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1 Introduction 
1.1 IL-6 family of cytokines 
 Cytokines are a group of low molecular weight regulatory peptides or proteins 
produced by multiple cell types such as lymphocytes, monocytes/macrophages, mast cells, 
eosinophils, and endothelial cells lining blood vessels. Each individual cytokine can have 
multiple functions depending on the cell that produces it and the target cell(s) on which it 
acts. Also, several different cytokines can have the same biological function. Cytokines 
can exert their effect through the bloodstream on distant target cells (endocrine), on target 
cells adjacent to those that produce them (paracrine) or on the same cell that produces the 
cytokine (autocrine). To express a certain cytokine the cell has to be exposed to a stimulus. 
For example, monocytes/macrophages secrete IL-1, IL-6 and TNF-α after contact with 
bacterial lipopolysaccharides [1]. IFN-β, TNF-α and viral infections stimulate the synthesis 
of IL-6 in fibroblasts [2, 3]. Cytokines act on target cells via binding to cell-surface 
receptors which leads to the activation of specific transcription genes resulting in the 
control of cell growth, differentiation or apoptosis.  
All members of the haematopoietic IL-6 cytokine family, also called gp130 
cytokine family, exert their biological effects via binding to a receptor homodimer of 
gp130 or a heterodimer of gp130/LIFR (gp130/OSMR, gp130/WSX-1). Gp130 as well as 
LIFR or OSMR are the signal transduction receptors (β-receptors) activated by binding of 
the cytokine. Some cytokines (IL-6, IL-11, CNTF) can not bind to β-receptors unless they 
first form a complex with a specific ligand binding receptor (α-receptor) (Tab1.1). α-
receptors are not involved in signaling. 
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Tab.1.1 IL-6 cytokine family and their receptors [7-9] 
cytokine β-receptor α-receptor 
IL-6 gp130, gp130 IL-6R 
IL-11 gp130, gp130 IL-11R 
CNTF gp130, LIFR CNTFR 
CLC gp130, LIFR CNTFR 
neuropoietin gp130, LIFR CNTFR 
LIF gp130, LIFR - 
OSM gp130, LIFR - 
OSM gp130, OSMR - 
IL-27(p28/EBI3) gp130, WSX-1 EBI3 
CT-1 gp130, LIFR unknown 
 
 
1.2 Signaling via IL-6/IL-6R 
As shown in Fig.1.1, IL-6 first binds to the membrane-bound non-signaling IL-6 
receptor (IL-6R) before the IL-6/IL-6R complex activates gp130 [4-6]. Homodimerisation 
of two gp130 molecules causes phosphorylation of receptor tyrosines by Janus-kinases 
(JAK1, JAK2, TYK2), which are constitutively associated with gp130 [7]. These 
phosphotyrosin motifs are docking sites for the signal transducers and activators of 
transcription STAT1/STAT3 factors which also become phosphorylated by the JAKs 
activity. Phosphorylation of the STAT factors leads to their dimerisation and relocalisation 
to the nucleus where they induce the transcription of target genes. STAT3-dependent gene 
expression causes upregulation of inhibitory proteins of the suppressor of cytokine 
signaling (SOCS) family that interfere with JAK activity [10-12]. Phosphorylation of 
gp130 also triggers the Ras/Raf/MAP-kinase pathway via adaptor proteins such as SHP-2, 
Grb2 and SOS, leading to activation of the transcription factors NF-IL-6 and AP-1 [7].  
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Fig. 1.1 Signaling pathways induced by IL-6. IL-6 first binds to the membrane-bound IL-6R and 
then to the gp130-homodimer to form the active cytokine complex. The signal transduction receptor 
gp130 is activated via phosphorylation by JAK. JAK phosphorylates also STAT molecules leading 
to their dimerisation and relocalisation to the nucleus where they induce the expression of target 
genes like the acute phase proteins or adaptorproteins (SHP-2, Grb2, SOS) to turn on the 
Ras/Raf/MAPK pathway.  SOCS expression causes downregulation of the cytokine signaling [7, 10-
12]. 
 
1.3 Soluble IL-6R and the phenomenon of transsignaling 
The IL-6R protein has been shown to exist in soluble as well as in membrane-bound 
form. The release of sIL-6R is regulated via two mechanisms. First, the soluble receptor 
that lacks cytoplasmic and membrane- spanning domains can be synthesised from an 
alternatively spliced mRNA [13-16]. The second mechanism is the proteolytic cleavage of 
the membrane-bound IL-6R from the cell surface [17-19]. The soluble form of the receptor 
can control the bioactivity and the pathophysiological effect of IL-6. 
Soluble IL-6R is still able to bind to IL-6 and the complex of IL-6/sIL-6R can 
stimulate target cells that do not express the IL-6R and are nonresponsive to IL-6 alone [5, 
8]. Interestingly, membrane-bound IL-6R is present on only a small number of cells, i. e. 
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hepatocytes, monocytes/macrophages and some lymphocytes, whereas gp130 is expressed 
by all cells in the body [21]. Therefore, cells which release sIL-6R render cells which only 
express gp130 responsive towards IL-6 [22-24]. This process has been termed 
“transsignaling” (Fig. 1.2) [21, 25-27]. Transsignaling cell types that are exclusively 
responsive to IL-6/sIL-6R but not to IL-6 alone include haematopoietic progenitor cells 
[21, 22], endothelial cells [28], osteoclasts [23], smooth muscle cells [29], and neuronal 
cells [24, 30]. 
gp130 IL-6R IL-6
cell A cell B
sheddaseshed sIL-6R alternatively
spliced sIL-6R
 
 
Fig. 1.2 Transsignaling of the soluble IL-6R. IL-6 classically activates cells by binding to the 
membrane-bound IL-6R followed by recruitment of two gp130 molecules which activates 
downstream signal cascades. A soluble IL-6R can be generated by proteolytic cleavage or by 
alternative splicing. IL-6/IL-6R complex associates with gp130 expressed on a cell which does not 
express the IL-6R and initiates signalling [21, 25-27]. 
 
 Transsignaling is regulated via the release of soluble IL-6 receptor and the presence 
of soluble gp130 (sgp130) in the serum [31]. Importantly, sgp130 inhibits only IL-6 effects 
that are mediated by the sIL-6R, but not those transmitted via the membrane-bound 
receptor [32].  
The agonistic properties of the soluble receptor/cytokine complex and the 
transsignaling phenomenon were also described for other cytokines of the IL-6 cytokine 
family such as IL-11 and CNTF [33, 34]. 
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1.4 The sIL-6R in diseases 
Transsignaling may be a pathogenetic factor in human diseases as diverse as 
multiple myeloma (MM), Castleman’s disease, prostate carcinoma, Crohn’s disease, 
systemic sclerosis, Still’s disease, osteoporosis and cardiovascular disease [27].  
In most autoimmune disorders the affected organ displays an infiltrate of 
mononuclear cells and very often vasculitic syndromes. The role of IL-6 and sIL-6R in the 
pathogenesis of such diseases is the regulation of leukocyte infiltration via activation of a 
positive autocrine feedback loop. Endothelial cells are unresponsive to IL-6, but can be 
stimulated by the IL-6/sIL-6R complex. Activated endothelial cells upregulate gp130 and 
LIFR and secrete monocyte attractant protein (MCP)-1, MCP-3, IL-8, IL-6, vascular cell 
adhesion molecule (VCAM)-1, intracellular adhesion molecule (ICAM)-1 and protein S, 
which provides the basis for leukocyte recruitment and adhesion [28, 35]. Leukocyte 
recruitment during acute inflammation is characterised by an initial infiltration of 
neutrophils [36], which are later replaced by mononuclear cells. The secreted IL-8 activates 
CXCR1 and induces shedding of the IL-6R from infiltrating neutrophils [37] that leads to 
activation of endothelial cells [38]. In this way, IL-6 and sIL-6R induce the expression of 
inflammatory molecules required for the recruitment of inflammatory cells found in 
vasculitis.    
A key factor in the pathogenesis of autoimmune diseases is the resistance of 
autoreactive cytotoxic CD8+-T-cells against apoptotic cell death. This can be a 
consequence of activation of STAT3 by the IL-6/sIL-6R complex and STAT3-dependent 
upregulation of anti-apoptotic genes [39]. Autoimmune reactions can arise in all tissues 
where uncontrolled/unlimited release of IL-6/sIL-6R occurs. 
Many neural cells only react to IL-6 in the presence of sIL-6R suggesting that 
transsignaling is an important event in neuronal differentiation and survival responses [30, 
40-43].  
The IL-6/sIL-6R complex plays a role in the pathogenesis of neoplastic diseases, for 
example multiple myeloma. Multiple myeloma cells do not express IL-6 but stimulate bone 
marrow stromal cells to produce high levels of IL-6 [44, 45]. IL-6 inhibits apoptosis of 
myeloma cells due to activation of STAT3 und upregulation of bcl-xL and mcl-1. In 
addition, shedding or secretion of the sIL-6R is induced [46]. Soluble IL-6R produced by 
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myeloma cells enhances IL-6 synthesis by bone marrow stromal cells (positive feedback 
loop). The IL-6/sIL-6R complex stimulates expression of metalloproteinases and VEGF 
[47] by bone marrow stromal cells and may activate osteoclasts [48]. These effects could 
be involved in angiogenesis, osteolytic lesions and chemoresistance frequently observed in 
patients with multiple myeloma [49-50]. 
 
1.5 Kaposi’s sarcoma associated herpesvirus 
Human herpesvirus type 8 (HHV-8) or Kaposi’s sarcoma associated herpesvirus 
was first identified by Chang et al [52] in Kaposi’s sarcoma tissues of acquired 
immunodeficiency syndrome patients and appears to be  the first member of the human γ-
herpesviruses (rhadinoviruses). HHV-8 is linked to the development of Kaposi’s sarcoma 
(KS) as well as primary effusion lymphoma (PEL) [53, 54] and multicentric Castelman’s 
disease (MCD) [55]. It has also been associated with multiple myeloma [56, 57]. Similar to 
other human herpesviruses, HHV-8 has a particular cell tropism, infecting predominantly 
endothelial and other mesenchymal cells, as well as B-lymphocytes. Like other 
rhadinoviruses, the viral genome consists of linear double-stranded DNA of about 165 kb 
and contains numerous open reading frames encoding cellular homologues, including a G-
protein-coupled receptor, macrophage inhibitory factors, cyclin D, bcl-2 and chemokine 
genes [58-61]. However, several of the homologous genes encoded by HHV-8 are not 
shared by other rhadionoviruses or any other known viruses. One of these genes encodes a 
structural equivalent of interleukin-6 with high similarity to cellular IL-6 and was therefore 
named viral interleukin 6 (vIL-6) [56, 62, 63].  
 
1.6 Structural and receptor-binding properties of viral IL-6                 
Although cellular and viral IL-6 proteins show only ~25% sequence homology 
(human: 24,7%, murine: 24,2%), the crystal structures of a receptor complexes 
demonstrated a strong relationship of the binding epitops to their receptors [64]. 
Viral interleukin-6 (vIL-6) has a protein fold typical for most cytokines, the so-
called four-helical bundle [65]. This consists of four antiparallel α-helices with up-up-
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down-down topology which are connected by three loops (Fig. 1.3). The receptor binding 
epitops have been identified for cellular IL-6 as well as for viral IL-6. Human IL-6 (huIL-
6) binds to its receptors via three distinct sites [65, 66]. Site I is formed by the C-terminal 
part of helix D and the C-terminal region of the AB-loop and interacts with the IL-6R. Site 
II on helix A and C, and site III on the initial part of the AB-loop and helix D bind to gp130  
 
 
Fig. 1.3 Schematic cartoon representation of vIL-6 structure. A vIL-6 ABCD 4-helix bundle 
connected by peptide loops is displayed in different colours. Site I, composed of the N-terminal 
region of the AB-loop and the C-terminal region of helix D, corresponds to the presumed site where 
huIL-6 would interact with IL-6R. Site II on helix A and C, and site III on the initial part of the AB-
loop and helix D represent binding surfaces to gp130. B vIL-6 is juxtaposed to gp130 in a tetrameric 
(2:2) signaling model. Site II of vIL-6 is occupied by the D2D3sites of one gp130 chain (yellow), 
and site III is occupied by the D1 site of another gp130 chain (red). Site I of vIL-6 is not occupied 
by gp130 and is sterically accessible for engagement by other molecules [68]. 
 
[67, 70]. As with cellular IL-6, the structure of vIL-6 has identified site II and site III as 
directly binding to gp130, the common signal transducer for the IL-6 family of cytokines 
[68,70]. Site I corresponds to the presumed site where human IL-6 would interact with the 
IL-6R. 
Despite similarities in their global structures, huIL-6 and vIL-6 differ in their mode 
of receptor usage [67, 70]. Viral IL-6 and huIL-6, like other cytokines of the IL-6 family, 
such as CNTF, LIF, OSM, CLC, CT-1, and IL-11, use the gp130 receptor for signal 
transduction [71]. In contrast to cellular IL-6, vIL-6 does not need to interact with the 
ligand-binding α-receptor IL-6R to induce signaling [72]. Viral IL-6 shows activity on cells 
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expressing only gp130, but not IL-6R. This suggests that vIL-6 directly binds to and 
activates gp130 [69, 70, 72, 73], which seems to play a decisive role in the manifestation of 
the vIL-6 activity and pathogenesis of diseases induced by vIL-6. 
Interestingly, G. Miller et al. [74] reason that N-glycosylation of vIL-6 is required 
for its binding and function. vIL-6 has an unused site I not occupied by gp130. The 
equivalent site in huIL-6 interacts with the IL-6R. N-glycosylation sites at N78 and N89 of 
the viral cytokine are located in the vicinity of site I (Fig. 1.4) and their use markedly 
enhanced binding to gp130. Although huIL-6 is N- and O-glycosylated, neither N-linked 
nor O-linked glycosylation is necessary for IL-6 receptor dependent binding to gp130 or 
signaling through JAK/STAT [75]. 
 
 
Fig. 1.4 Localisation of the N-glycosylation sites of vIL-6 in a schematic representation of the 
crystal structure of the vIL-6/gp130 complex.  Site I of vIL-6 is not a contact site with gp130, but 
corresponds to a site where huIL-6 interacts with IL-6R. N78 (yellow) and N89 (red) are highlighted 
as spacefilling residues and are shown to occupy site I, but not sites II or III.  
 
1.7 Biological activity of viral IL-6 compared to human IL-6 
Viral IL-6 has been shown to mimic a number of huIL-6 activities such as 
stimulating IL-6-dependent B-cell line growth [76] and activating the JAK/STAT-signal 
transduction pathway in HepG2 cells [77] as well as the Ras/Raf/MAPK pathway in MH60 
and B9 cell lines [78]. Human IL-6 is expressed by a number of cell types including B and 
T lymphocytes, monocytes, fibroblasts, keratinocytes, bone marrow stromal cells, 
endothelial cells, and astrocytes. The wide range of biological activities attributed to huIL-
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6 includes proliferation of lymphocytes and stem cells, differentiation of B cells and 
osteoclasts, induction of acute phase proteins in hepatocytes, and promotion of neuronal 
regeneration [79]. HuIL-6 serves as a growth factor for multiple myeloma and 
plasmacytoma cells [80]. vIL-6 is expressed in HHV-8-infected B cells and endothelial 
cells and induces proliferation, angiogenesis, and hematopoiesis in IL-6-dependent cell 
lineages [60, 69]. Viral IL-6 can serve as an autocrine growth factor for PEL cell lines [81]. 
Expression of vIL-6 accelerates hematopoiesis and induces vascular endothelial growth 
factor (VEGF), a factor implicated in PEL and Kaposi’s sarcoma pathogenesis [82]. 
However, the precise role of vIL-6 in HHV-8 pathogenesis is not well understood. Viral 
IL-6 may act as an antiapoptotic factor for survival of HHV-8-infected cells and/or 
promote the proliferation of HHV-8-infected cells or potential host cells. In lymphoma 
cells infected with HHV-8 the viral cytokine protects cells against innate immune defenses 
triggered by viral infection [83, 84] via blocking of interferon signaling [85].  
Alongside huIL-6 being the central regulator of the hepatic acute-phase response 
[86, 87], vIL-6 elicits a local acute-phase response in human primary Kaposi’s sarcoma cell 
cultures. The induction of the acute-phase protein pentraxin-3 may contribute to local 
tissue damage and the attraction of an inflammatory phenotype [88]. 
 
1.8 Hyper IL-6 and viral IL-6 mimicry of transsignaling 
To exert their function cytokines have to bind to the receptor complex on the 
membrane. After binding to the receptor complex, signaling occurs within the cell 
eventually leading to transcriptional induction of target genes. The receptor complex of the 
IL-6 family of cytokines includes two or three receptor subunits (Tab. 1.1). The 
composition of the signal competent receptor complex is crucial for cytokine function. For 
example, LIF can stimulate cells expressing gp130 and LIFR, such as hematopoietic and 
epithelial cells, hepatoma and breast cancer cells [89-92]. CNTF stimulates cells expressing 
gp130, LIFR and CNTFR like neuronal cells, skeletal muscle cells, bone marrow stromal 
cells, hepatocytes and adipocytes [93-95]. IL-6 acts on hepatocytes, 
monocytes/macrophages and some lymphocytes expressing IL-6R and gp130 [26, 27]. 
Viral IL-6 seems to be the only cytokine which only requires gp130 to transduce the signal 
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and is able to affect all cells in the body, including normal human vascular smooth muscle 
cells, hematopoietic progenitor cells and Kaposi’s sarcoma cells [63].  
Some years ago, a recombinant cytokine with the property to induce signal 
transduction only via gp130 was designed and named Hyper-IL-6 (HIL-6) [96]. Hyper IL-6 
is a fusion protein of huIL-6 and its soluble receptor sIL-6R connected by a flexible 
polypeptide linker. It has been shown that Hyper-IL-6 is able to stimulate the proliferation 
of cells only expressing gp130 [72]. Interestingly, the fusion protein exhibits a markedly 
increased bioactivity as compared to IL-6 and sIL-6R. The concentration of Hyper-IL-6 
needed for full stimulation of murine Baf/3-cells stably transfected with gp130, is 2-3 
orders lower than that needed of the two separate components IL-6 and IL-6R. Also, the 
expression of the acute-phase protein haptoglobin can be induced by much lower 
concentrations of Hyper-IL-6 compared to the combination of IL-6 and IL-6R. Such 
potential applications make Hyper-IL-6 a promising ex vivo or even in vivo therapeutical 
agent [97, 98]. 
The mode of action of viral IL-6 and Hyper-IL-6 can be compared with the IL-
6/sIL-6R complex and seems to mimic transsignaling. Although the vIL-6 activity is lower 
than the one of Hyper-IL-6 or the combination huIL-6/sIL-6R, vIL-6 is unique in that it is a 
natural cytokine capable to induce signal transduction directly via gp130 without the 
interaction with the soluble form of the α-receptor. Hence, vIL-6 can stimulate a broader 
spectrum of target cells than huIL-6. Like the combination of huIL-6 and sIL-6R, but not 
huIL-6 alone, vIL-6 can stimulate the expansion of hematopoietic progenitor cells and 
affect different neuronal cells [42, 69, 72, 99, 100]. 
 
1.9 Natural neutralisation of IL-6/sIL-6R 
Because gp130 is ubiquitously expressed, the complex of sIL-6R and IL-6 could 
theoretically stimulate all cells of the body. In several cell culture and animal models 
soluble gp130 (sgp130), generated by translation from differentially spliced mRNA [101], 
specifically blocked IL-6 responses dependent on sIL-6R. In contrast, responses via the 
membrane-bound IL-6R remained unaffected [32]. It has been shown that sgp130 can not 
block IL-6-induced activation of IL-6R expressing cells, but abrogates activation of 
transsignaling cells (Fig. 1.5). In this way, sgp130 acts as a regulator of transsignaling and 
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could be the natural neutralisation agent of the IL-6/sIL-6R complex [32]. Sgp130 
concentrations have been shown to be increased in patients with systematic sclerosis [102], 
multiple sclerosis [103] and melanoma cells [104]. 
Recombinant sgp130Fc, which is the extracellular domain of human or murine 
gp130 fused to the constant region of a human IgG1 heavy chain [32], is expected to be a 
valuable therapeutic tool to specifically block disease states in which sIL-6R transsignaling 
responses exist [36, 39, 105, 106]. 
 
gp130 IL-6R IL-6sgp130 sIL-6R
 
Fig. 1.5 Soluble gp130 is the natural inhibitor of IL-6/sIL-6R responses. A  IL-6 can not bind to 
sgp130. Soluble gp130 has no access to IL-6 complexed by IL-6R and two molecules of membrane-
bound gp130 and exhibits no inhibitory activity. B The IL-6/sIL-6R complex can equally bind to 
both membrane-bound and soluble gp130. IL-6/sIL-6R binding to sgp130 leads to competitive 
inhibition of its response [32]. 
 
1.10 Recombinant antibodies and strategies of vIL-6 
neutralisation 
Because vIL-6 binds directly to gp130, an Fc fusion protein of gp130 can be an 
inhibitor of vIL-6. Proliferation of Baf/3-gp130 cells upon stimulation with vIL-6 is 
blocked after adding 1µg/ml of recombinant sgp130Fc [72]. The prospects of neutralisation 
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of viral IL-6 hold great promise for therapy in vIL-6 associated diseases. sgp130Fc can be 
helpful for the suppression of transsignaling via IL-6/sIL-6R and via vIL-6 in various 
disease states. Molecular strategies for inhibition of signaling induced by vIL-6, but not by 
IL-6/sIL-6R can be based on the production of an antibody against viral IL-6 capable of 
neutralising the vIL-6 effect or destroying the HHV-8-infected cells.  
Antibodies constitute a modular defence system of our body created by evolution to 
identify and mark any foreign intruder. By combination of a set of variant gene cassettes 
with additional mutation mechanisms, more than a billion different antibody-sequences can 
be generated. The genetic material for this huge “library” of different antibodies is stored in 
the B-cell pool of our lymphatic tissue. 
Naturally occurring antibodies produced by B-cells consist of four polypeptide 
chains (Fig. 1.6 A). Two heavy chains (composed of one variable and three constant 
domains) and two light chains (composed of one variable and one constant domain) are 
held together by disulphide bonds. Antigen recognition by the antibody occurs via the  
 
Fv
VH
VL VL
CL CL
CH 3 CH 3
CH 2 CH 2
CH 1 CH 1
VH
CDRs
A B CDR1 CDR2 CDR3
hypervariable
regions
antigen-
binding
site
 
Fig. 1.6 Structure of an antibody molecule. A Schematic representation of the structure illustrating  
the four-chain composition and the separate domains comprising each chain: VL- variable domain 
of light chain; CL- constant domain of light chain; VH- variable domain of heavy chain; CH- 
constant domain of heavy chain; variable domains of both, light and heavy chain, form the variable 
fragment (Fv) of the antibody; CDR- complementarity-determing region. B The hypervariable 
regions (CDRs) lie in discrete loops of the folded structure and form the antigen-binding site [115]. 
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variable regions (VH and VL). Each variable domain contains three hypervariable regions 
known as complementarity-determining regions, or CDRs. The CDRs together form the 
antigen binding paratope (Fig. 1.6 B). 
Monoclonal antibodies are clonal populations of antibodies with the same 
specificity. They are very important research tools and find increasing use in various 
therapies [107-110]. Such antibodies are generated by fusing B-cells from immunised 
animals with myeloma cells. This generates a population of immortal hybridomas, from 
which the required clones can be selected. However, the therapeutic application of such 
antibodies produced by animal cells is limited by reactions of the human immune system 
leading to rejection of the animal proteins [111]. This can be reduced in part by humanizing 
the antibody by grafting the CDRs from the parent monoclonal into the backbone of a 
human IgG antibody [112]. 
New fascinating perspectives have been revealed by development of recombinant 
antibody libraries which can be screened for specific monoclonal antibodies outside the 
human body without the need of animal immunisation [113]. For this purpose, huge 
antibody gene libraries have been created. This is usually achieved by PCR-amplification 
from B-lymphocyte cDNA. Alternatively, antibody genes can be constructed in vitro by 
gene synthesis using “randomised wobble”-primers and inclusion of these foreign random 
sequences into the CDR regions. A combination of both methods also has been published 
[113-116]. The antibody library does not consist of native antibodies, but of single 
polypeptides retaining the antigen binding properties of the monoclonal antibody (Fv-
variable fragment or Fab-antigen-binding fragment). Such polypeptides are called 
recombinant antibodies (Fig. 1.7A).  To screen a library that contains many millions of 
different clones, a selection system is required with an efficiency comparable to that of the 
immune system. This can be achieved by displaying the antibodies on the surface of 
bacteriophages containing the antibody’s gene, in analogy to the expression of the IgM 
antibodies on the surface of unactivated B-lymphocytes. One example is the filamentous 
bacteriophage M13 [116]. A phage display library is a heterogeneous mixture of phage 
clones, each displaying a different single-chain Fv peptide (scFv) on its surface. Clones 
specific for the antigen can be isolated by affinity selection and used for production of the 
antibody fragment in E.coli or other suitable host organisms. 
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The screening procedures provide the power to select one from over a billion 
different expression clones in solution. The screened libraries can contain synthetic 
sequences, e. g. randomised antigen binding regions, or new combinations of light/heavy 
chains, thus creating the potential for generating human antibodies which could never be 
found in the blood stream. By random or designed mutations, the affinity or specificity of 
the antigen binding can be improved, reaching affinities observed with natural antibodies. 
These methods opened the way to use recombinant antibodies in research, diagnosis and 
therapy. For example, human anti mouse immune response, a major obstacle in patient 
treatment or in vivo diagnosis with conventional mouse monoclonal antibodies, can be 
avoided using recombinant human antibody fragments [111, 117].  
Furthermore, genetic coupling of the antibody to a heterologous protein by fusion of 
gene fragments generates possibilities for immunotargeting. Immunotargeting employs the 
affinity of the antibody part to direct the activity of the heterologous protein towards the 
antigen. 
To target vIL-6-secreting cells, a bispecific antibody (diabody) could be produced. 
This diabody is a recombinant antibody against vIL-6 conjugated with a T-cell receptor 
activating antibody (Fig. 1.7B). Cells secreting vIL-6 can be specifically killed by human 
T-cells when treated with bispecific antibodies binding to viral IL-6 and the T-cell receptor 
complex. Cells that do not express vIL-6 are unaffected. Such a strategy has been 
successfully employed for scFv antibodies specific for human IL-6 [118, 119]. 
A completely different strategy would exploit the intracellular recognition of vIL-6. 
Using this strategy, cells which synthesise the viral cytokine could be phenotypically 
changed not to secrete vIL-6. By using the ER targeting KDEL protein sequence (Lys-Asp-
Glu-Leu) [118, 120] that can be added to an antibody at cDNA level (Fig. 1.7C), it should 
be possible to anchor such a fusion-antibody in the endoplasmic reticulum of an HHV-8 
infected cell. Viral IL-6 on the way to the cell membrane would bind to this antibody and 
be retained within the cell.  Thus, it could be possible to suppress the cellular secretion of 
the viral cytokine. 
Potent cell killing agents are immunotoxins [121] that are emerging as therapeutic 
agents for the treatment of cancer and some immunological disorders [122-126]. They are 
constructed by attaching antibodies to cellular toxins, such as Pseudomonas exotoxin A 
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(PE). An antibody against vIL-6 fused to PE38 (Fig. 1.7D) could specifically kill the cells 
binding vIL-6.   
 
VH VL
VH VL
VH VL
vIL-6
OKT3
VH VL
PE38
VH VL
KDEL
A
D
B
C
 
Fig. 1.7 Recombinant antibody fragments. A scFv- single-chain Fv fragment; B bispecific 
diabody, which is the scFv against vIL-6 conjugated with the OKT3 antibody; C scFv fused with the 
endoplasmic retention sequence KDEL; D scFv fused with the cellular toxin PE38. 
 
1.11 Aim of the study 
Viral IL-6 (vIL-6) encoded by human herpesvirus 8 (HHV-8) is a structural 
homologue of human and murine IL-6 and affects the cells via binding to the signal 
transducer gp130. vIL-6 is believed to be important in the pathogenesis of HHV-8 caused 
diseases including Kaposi’s sarcoma as well as primary effusion lymphoma, multicentic 
Castelman’s disease and perhaps multiple myeloma [56, 57]. The neutralisation of vIL-6 
biological activity is thought to be helpful to combat these diseases. Therefore, the aim of 
this study was to generate recombinant antibodies against vIL-6 and to develop strategies 
for the targeting or elimination of cells expressing vIL-6. 
In this study the recombinant vIL-6 had to be expressed, purified and tested for 
biological activity. Active purified vIL-6 could be used as antigen for phage display to 
isolate and later on to characterise the recombinant anti-vIL-6 antibodies. 
M. Kovaleva „Recombinant antibodies against viral interleukin-6“                                               Introduction 
 16 
The human recombinant antibodies against vIL-6 had to be screened using phage 
display technology. Selected antibodies had to be expressed, purified and characterised. 
The specificity and affinity of the antibodies to vIL-6 needed to be analysed and their 
ability to neutralise vIL-6 had to be tested. 
The last objective of the study was to eliminate vIL-6 secretion using an antibody 
fused to the endoplasmic retention sequence KDEL. It was to be shown that vIL-6 can 
intracellularly bind to such an antibody and be retained in the endoplasmic reticulum. 
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2 Materials and methods 
2.1 Materials 
Bacterial strains: 
BL21 (Novagen) F- ompT hsdSB (rB-mB-)gal dcm (DE3) 
BL21pLysS (Novagen) F- ompT hsdSB (rB-mB-)gal dcm (DE3)pLysS (CamR) 
DH5α (MBI Fermentas) F-gyrA96(Nalr) recA1 relA1 endA1 thri-1 hsdR17 (rk-mk+) 
glnV44 deoR ∆(lacZYA-argF) U169[φ80d ∆(lacZ)M15] 
TG1 (Amersham) SupE hsd∆5 thi ∆(lac-proAB) F’[traD36 proAB+ laclqlacZ∆M15] 
HB2151 (Amersham) K12 ara ∆(lac-pro) thi/F’ pro A+B+ laclqlacZ∆M15 
Cell lines: 
COS-7 (african green monkey kidney fibroblast cell line) 
HepG2 (human hepatocarcinoma cell line) 
Baf/3-gp130 (murine IL-3 dependent pro-B-cells, stably transfected with gp130 [127]) 
Baf/3-gp130, IL-6R (murine IL-3 dependent pro-B-cells, stably transfected with gp130 
and IL-6R [128]) 
EBNA-293 (human embryonic kidney cell line, stably expressed EBNA-1 gene of 
epstein barr virus, Invitrogen) 
Phage library: 
Human Single Framework scFv Libraries, Tomlinson A+B (Tomlinson, T., MRC, 
Centre for Protein Engineering, Cambridge, UK) 
Phagemids and vectors: 
pIT1  (Invitrogen)                    ampr 
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pET16b (Novagen)                  ampr 
pET22b (Novagen)                  ampr 
pET23a  (Novagen)                 ampr 
p409B (modified in our lab)    ampr 
pcDNA3.1 (Invitrogen)            ampr 
pESL (modified in our lab)       kanr 
Antibiotics: 
Ampicillin     to 50µg/ml 
Kanamycin    to 50µg/ml 
Media: 
LB medium:  
5g/l yeast extract, 10g/l tryptone, 10g/l NaCl  
LB-agar:  
5g/l yeast extract, 10g/l tryptone, 10g/l NaCl, 15g/l agar 
TYE medium:  
5g/l yeast extract, 10g/l tryptone, 8g/l NaCl, 15g/l agar 
2xTY medium:  
10g/l yeast extract, 16g/l tryptone, 5g/l NaCl 
cell growth medium:  
DMEM (PAA), 10%FCS, 60mg/l penicillin, 100mg/l streptomycin 
Enzymes: 
All used restriction endonucleases, T4 polynucleotide kinase, T4 DNA ligase, Pfu DNA 
polymerase, calf intestine alkaline phosphatase were from MBI Fermentas. 
Enzyme substrates: 
p-nitrophenyl phosphate tablets (Sigma) – alkaline phosphatase substrat for ELISA (1 
tablet : 15ml diethanolamine buffer) 
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ECL plus Western blotting detection system (Amersham) 
Antibodies and antiserums: 
Anti-vIL-6 rabbit serum [69], 1:10.000 
Anti-flag M2 monoclonal antibody (Sigma), 1:1000 
Anti-myc monoclonal antibody 9E10 (research group Phytoantibodies, IPK, 
Gatersleben), 1:50 
Anti-mouse alkaline phosphatase conjugate (Sigma), 1:2000 
Anti-rabbit IgG goat peroxidase conjugate (Pierce), 1:10.000 
Anti-mouse IgG goat peroxidase conjugate (Pierce), 1:10.000 
Anti-STAT3-antibody (Biolabs), 1:1000 
Anti-phospho-STAT3-antibody (Biolabs), 1:1000 
Anti-mouse Alexa Fluor 594 goat antibody (Molecular Probes), 1:500-1:1500 
Recombinant cytokines: 
Hyper-IL-6 (5ng/ml for cell cultivation) 
Human-IL-6 (5ng/ml for cell cultivation) 
Molecular markers: 
DNA molecular weight marker X (Roche) 
Protein molecular weight marker #SM0431 (Fermentas) 
Prestained protein molecular weight marker #SM0441 (Fermentas) 
Full range protein molecular weight Rainbow marker RPN800 (Amersham) 
Chemicals: 
All used chemicals were from ROTH or MERCK. 
Kits: 
CONCERT Rapid Gel Extraction System (Gibco BRL) 
NucleoSpin Plasmid DNA Purification Kit (Macherey-Nagel) 
Gateway LR-clonase Enzyme Mix (Gibco BRL) 
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SlowFade Light Antifade Kit (Molecular Probes) 
Reagents for protein purification: 
Ni-NTA spin column (Amersham) 
Ni-NTA agarose (Qiagen) 
Dynabeads TALON (Dynal) 
Buffers: 
TBS: 
50mM Tris pH=7.6, 200mM NaCl 
TBS-T: 
50mM Tris pH=7.6, 200mM NaCl, 0.05%Tween-20 
PBS:  
250mM NaCl, 20mM KCl, 48mM Na2HPO4, 1.5mM KH2PO4 
PBS-T: 
250mM NaCl, 20mM KCl, 48mM Na2HPO4, 1.5mM KH2PO4, 0.05%Tween-20 
Diethanolamine buffer: 
97ml diethanolamine, 0.1g MgCl2, 0.2g NaN3, add 1l H20, pH=9.8 
12,5% -SDS-electrophoresis gel: 
3.75ml H2O, 3ml 1.5M TrispH=8.8, 120µl 10%SDS, 5ml 30% acrylamid/0.8% 
bisacrylamid, 120µl 10% APS, 6µl TEMED 
7,5% -SDS-electrophoresis gel: 
4.9ml H2O, 2.5ml 1.5M TrispH=8.8, 100µl 10%SDS, 2.5ml 30% acrylamid/0.8% 
bisacrylamid, 100µl 10% APS, 10 µl TEMED 
4% -SDS-electrophoresis stacking gel: 
6.1ml H2O, 2.5ml 0.5M TrispH=6.8, 100µl 10%SDS, 1.33ml 30% acrylamid/0.8% 
bisacrylamid, 50µl 10% APS, 10µl TEMED 
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2 x SDS gel-loading buffer (Laemmli [129]): 
100mM Tris pH=6.8, 4% SDS, 0.2% bromphenol blue, 20% glycerol 
Tris-glycine electrophoresis buffer: 
25mM Tris, 250mM glycine pH=8.3, 0.1% SDS 
Solutions for silverstaining: 
Fixate I: 40% methanol, 10% acetic acid 
Fixate II: 10% ethanol, 15% acetic acid 
Reducer: 0.2g reducer after Farmer (TETENAL) in 50ml H2O 
Silversolution: 0.1g AgNO3 in 50ml H2O 
Developer: 2,9g Na2CO3, 40µl formaldehyde  
Coomassie solution: 
1g/l Coomassie R250, 40% methanol, 10% acetic acid 
Destaining solution: 
40% Methanol, 10% acetic acid 
Transfer buffer: 
39mM glycine, 48mM Tris base, 20% methanol 
Stripping buffer: 
2% SDS, 62.5mM Tris, 100mM β-mercaptoethanol 
Software: 
Prism (PPC) Alias, DNA Strider 1.3f12 Alias, EditView 1.0.1, Image reader LAS-1000, 
TECAN 5.0a, Quantity One, Fastfit 2.01, IAsys 2. 
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2.2 Methods 
2.2.1 Cloning  
Plasmid DNAs were isolated using the NucleoSpin Plasmid DNA Purification Kit 
(Macherey-Nagel), restriction digests and ligations were prepared using enzymes from 
Fermentas according to the manufacturer’s instructions. The LR-clonase reaction was 
done as described in the application guide for the Gateway Cloning Technology (Gibco 
BRL). 
 
2.2.2 Polymerase Chain Reaction (PCR) and Splicing by 
Overlap Extension - PCR (SOE-PCR) 
The following PCR protocol was employed: 1-5ng of template, 0.2µM dNTPs, 5µM 
primers, 1U Pfu-Polymerase and 1x reaction buffer were mixed and the volume made 
up to 50 µl with sterile water. For the reaction, the Robocycler Gradient 96 
(STRATAGENE) was used and programmed as follows: 
95°C – 5min 
95°C – 45sec 
55°C – 90sec             27 cycles 
72°C – 120sec 
72°C – 3min 
SOE-PCR was used for amplification of SP-MAV (signal peptide of huIL-6 with MAV 
sequence) to clone a construct for eukaryotic expression of MAV. The signal peptide of 
huIL-6 (SP) was amplified by PCR using the primers MK104 and MK704 (Fig. 3.2.28 A). 
The reverse primer MK704 included the N-terminal sequence of MAV (7 a.a. = 21 bp). 
Thus, the PCR product of the signal peptide contained the N-terminal part of the MAV 
sequence at its C-terminal. The MAV sequence was amplified from pIT1-MAV employing 
the primers MK304 and MK404. The reverse primer MK404 included 12 nucleotides 
encoding the KDEL and the translational stop-codon TAG. The PCR-products of SP and 
MAV were applied to an agarose gel, extracted by CONCERT Rapid Gel Extraction 
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System (GibcoBRL) and used for Splicing by Overlap Extension (SOE)-PCR [156-159]. 
The PCR-products of MAV and SP were mixed and denaturised. The ssDNA of MAV 
annealed to the complementary ssDNA of the signal peptide. SOE-PCR was done under 
same conditions as PCR in 50µl reaction volume containing 5µl of amplified and extracted 
SP, 5µl of amplified and extracted MAV, 5µM terminal primers (MK104 and MK404), 
0.2µM dNTPs, 1U Pfu-Polymerase and 1x reaction buffer. 
 
2.2.3 Transformation of bacteria by heat-shock 
Stored chemically competent bacterial cells DH5α were refrozen on ice. DNA samples 
or aliquots of a ligation mixture (5µl), chilled on ice, were added to 100µl competent 
cells, mixed and incubated on ice for 20min. The transformation was achieved by heat-
shock at 42°C for 90sec and subsequent incubation on ice for 3min. 350µl of LB 
medium were added to each sample and incubated at 37°C for 45min to allow the 
bacterial cells to recover. Transformed cells were plated onto LB agar containing the 
selective antibiotic and grown overnight at 37°C. 
 
2.2.4 Preparation of recombinant vIL-6 in the bacterial 
expression system 
A bacterial culture of E. coli BL21plysS transformed with the plasmid pET16b-vIL-6-
his was grown under shaking at 37°C to OD600=0.5. The expression of vIL-6-his was 
induced by adding 0.4mM IPTG for 4h. Afterwards, the bacterial culture was 
centrifuged at 6000g for 20 min, the supernatant was discarded and the bacterial cells 
were lysed using the French Press (FRENCH PRESSURE CELL PRESS, 
ThermoSpectronic) [130]. Inclusion bodies were separated from soluble proteins by 
centrifugation at 13000g for 1h. After three times washing with PBS, the inclusion 
bodies were dissolved in 6M guanidine hydrochloride and applied to a 1ml Ni-NTA 
column (Amersham Pharmacia). Before that, the column was equilibrated with 50mM 
phosphate-buffer pH=7.4 containing 500mM NaCl and 6M guanidine hydrochloride. 
After application of the proteins, the column was washed again, first with the same 
buffer, then with 50mM Tris-buffer pH=7.4. Recombinant vIL-6-his was eluted with 
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0.5M imidazole in 50mM Tris-buffer pH=7.4 and dialysed to 50mM Tris-buffer pH=7.4 
without imidazole. 
 
2.2.5 Preparation of recombinant vIL-6 in the eukaryotic 
expression system 
Stably transfected EBNA cells were grown in culture medium containing 10% FCS to 
80-100% confluency. Then, the medium was changed to FCS-free medium and 
expressed vIL-6 protein was collected in the supernatant for 7 days. vIL-6 expressed in 
transiently transfected COS-7 cells (2.2.4) was also collected in FCS-free medium for 
about 5-7 days up to the point where the medium turned yellow. Cell supernatants were 
centrifuged to clean them from cell debris and incubated at RT with 300 µl/50 ml Ni-
NTA agarose (Qiagen) for 2h. The agarose was washed with phosphate buffer 
containing 500 mM NaCl at pH=7.4, and recombinant vIL-6 was eluted with 1 ml of the 
same buffer containing 0.5 M imidazole.  
 
2.2.6 Transient transfection of COS-7 cells using DEAE-
dextran  
COS-7 cells were splitted to be 70-80% confluent the next day. Before transfection, the 
culture medium was changed to medium containing 75 µM chloroquine. For one 10 cm 
Petri dish, 5µg plasmid DNA was added to 435µl chloroquine-containing medium and 
65µl DEAE-dextran (4mg/ml). This mixture was dropwise added to the cells followed 
by 4h incubation at 37°C and 5% CO2. Subsequently, the medium was removed and the 
cells were treated with 10% DMSO containing DMEM at RT for 7min. Afterwords, the 
cells were washed with PBS and new DMEM was added. 
 
2.2.7 SDS-PAGE and gel staining 
SDS-polyacrylamide gel electrophoresis was carried out at 150 V for about 1h using the 
BIO-RAD system. Separated proteins were stained with Coomassie-solution at RT for 
2h or silver. For silverstaining, the gel was incubated in fixate I and fixate II for 5 min 
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each. After 5 times washing for 1 min with 60°C warm H2O, the gel was incubated in 
reducer for 30sec. After another washing step, the gel was stained with silver solution 
for 12min. Then, the gel was washed with RT- H2O for 90sec and developed (see 2.1). 
The reaction was stopped with 10% acetic acid.  
 
2.2.8 Proliferation assay 
For the proliferation assay, the Baf/3 transfectants Baf/3-gp130 and Baf/3-gp130, IL-6R 
were used. Cultured cells were washed three times with PBS to remove the cytokine 
used to sustain proliferation. Afterwards, the cells (5 x 103/well of 96-well microtiter 
plate) were incubated in the presence of different cytokine concentrations for 68h and 
subsequently puls-labeled with 0.25µCi [3H]thymidine for 4h. Proliferation rates were 
measured by harvesting the cells on glass filters, and the incorporated radioactivity was 
determined by scintillation counting. For each cytokine concentration, the proliferation 
assay was performed at least three times in triplicates. 
 
2.2.9 Selection of vIL-6 specific phages from the phage display 
libraries 
2.2.9.1 Production of helper phage 
200 µl of the E. coli TG1 culture (OD600=0.2) were infected with 10µl of 1:102, 1:104, 
1:106 dilutions of helper phage M13KO7, incubated at 37°C for 30 min and plated on 
TYE medium for overnight growth at 37°C. Individual clones were picked into 5 ml of 
exponentially growing E. coli TG1 cultures and incubated with shaking at 37°C for 2h. 
Phage-infected TG1 culture was diluted with 500 ml of 2xTY and grown with shaking 
at 37°C for 1h. Thereafter, kanamycin was added to a final concentration of 50 µg/ml 
and the culture was incubated with shaking at 30°C overnight. The cells were spun 
down at 10000g for 15min, and the phage particles were precipitated from the 
supernatant by adding 100ml of PEG/NaCl solution and incubation on ice for 1h. 
Precipitated phage particles were collected by centrifugation at 10000g for 30min and 
then resuspended in 8ml TE buffer. Phage precipitation was repeated by 
supplementation with 2ml PEG/NaCl solution to the phage suspension on ice for 20min 
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before the phages were collected by centrifugation at 3000g for 30min. The phage pellet 
was resuspended in PBS and spun again at 10000g for 10min to clean the phage 
particles from bacterial cell debris. The helper phage particles were resuspended in PBS 
with 15% glycerol for storage at -70°C.  
Titration of the phage stock was done by infection of 1ml E. coli TG1 culture 
(OD600=0.4) with 1µl of 1:1000 phage stock dilution in PBS. 50µl of the infected culture 
and 50µl of its dilutions 1:102, 1:104, 1:106 with 2xTY were plated on TYE medium 
containing 50µg/ml kanamycin and 1% glucose. Phage plaques were counted after 
overnight incubation at 37°C. 
2.2.9.2 Selection on immunotubes 
Immunotubes (3 or more per library) were coated with 100µl 10µg/ml flag-vIL-6-his 
solution in PBS and incubated at room temperature overnight. To block the free binding 
sites of the tubes, they were treated with 200µl 2% BSA in PBS for 2h. After blocking, 
the tubes were loaded with 1012-13 phage particles diluted in 100µl 2%BSA and 
incubated 30 min with shaking and 60 min without. The tubes were washed 20 times 
with PBS containing 0.1% Tween-20. The phage particles were eluted by adding 90µl 
100mM triethylamine per tube and shaking for 10min. The solution containing the 
eluted phages was neutralised by supplementation with 0.5 volume 1M Tris pH=7.4. 
The phage particles were amplified by infection of E. coli TG1 for the next round of 
phage selection. 9ml of TG1 fresh culture at OD600=0.4 were infected with the phage 
particles by incubation at 37°C for 30 min. To determine the phage titre, 50µl of the 
stock culture and its dilution (10-2, 10-4, 10-6) were plated on TYE medium containing 
100µl/ml ampicillin and 1% glucose. The infected culture was centrifuged at 3000g for 
10 min. The cell pellet was resuspendend in 1 ml 2xTY medium and plated on a Bio-
Assay dish containing TYE with 100µl/ml ampicillin and 1% glucose for overnight 
growth at 37°C with shaking. Colonies were scraped with a glass spreader from the agar 
using 5ml 2xTY supplemented with 15% glycerol. 50µl of this suspension were 
inoculated to 50 ml of 2xTY containing 100µl/ml ampicillin and 1% glucose and grown 
with shaking at 37°C to OD600=0.4. 5x1010 helper phage particles were added to 10ml of 
the bacterial culture and incubated without shaking in a 37°C water bath for 30 min. 
Subsequently, the cells were centrifuged at 3000g for 15 min, resuspended in 50ml 
2xTY containing 100µl/ml ampicillin and 50µl/ml kanamycin and incubated with 
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shaking at 30°C overnight. The cells were again centrifuged at 3000g for 15 min, and 
the phages were precipitated from 40 ml of supernatant by adding 10ml PEG/NaCl and 
incubation on ice for 1h. After centrifugation at 3000g for 30 min, the pellet containing 
the phage particles was resuspended in 1ml PBS and centrifuged at 11000g for 10 min 
to remove bacterial debris. The supernatant, i.e. the phage solution, was used for the 
next round of selection. 
2.2.9.3 Preparation of soluble scFvs 
 For the preparation of soluble scFvs, 200µl of the non-suppressor bacterial strain E. 
coli HB2152 were infected with 10µl of the eluted phages and incubated at 37°C for 30 
min without shaking. 2µl of bacterial culture were inoculated into 175µl 2xTY medium 
containing 100µl/ml ampicillin and 0.1% glucose and grown for 3h at 37°C with 
shaking. The expression of soluble scFvs was induced by adding 1mM IPTG and 
overnight shaking at 30°C. The bacterial culture was centrifuged at 1800g for 10 min 
and 50µl supernatant was used as primary antibody solution for the scFv ELISA. 
 
2.2.10 Soluble scFv ELISA 
A 96 well microtiter plate was coated with 100µl of 10µg/ml recombinant vIL-6 (or 
other antigens for cross-reactivity ELISA) and incubated at RT overnight. For blocking, 
200µl 3% BSA/PBS were loaded per well and incubated for 2 h. Then, 100µl of cell 
supernatant containing soluble scFv (2.2.11.3) diluted 1:2 with 2% BSA/PBS-T were 
applied per well and incubated at 25°C for 1h. The plate was washed 5 times with PBS-
T to remove unbound scFv. 100µl of monoclonal anti-myc antibody 9E10 diluted 1:50 
in 1% BSA/PBS-T were loaded per well and incubated for 1h. After 5 times washing 
with PBS-T, 100µl/well of anti-mouse IgG conjugated with alkaline phosphate (1:2000 
in 1% BSA/ PBS-T) were added and the plate incubated at RT for 1h.  5 times washing 
was followed by adding 100µl/well substrate for alkaline phosphate (1mg/ml p-
nitrophenylphosphate in diethanolamine buffer) and 15 min incubation at 37°C. The 
colour intensity was measured as extinction at 405nm using an ELISA reader. The 
results were analysed by Microsoft Excel. 
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2.2.11 Expression of scFv in bacterial cells E.coli BL21 
E. coli BL21 bacteria were transformed with the plasmid pET23a-MAV encoding the 
scFv. 1 litre LB medium containing 50µl/ml ampicillin was inoculated with 2ml 
overnight culture of transformed E. coli BL21 and grown with shaking at 37°C to 
OD600=0.5. The periplasmic expression of MAV was induced by adding 0.4mM IPTG 
and overnight shaking at 30°C. The bacterial culture was centrifuged at 6000g for 20 
min. The supernatant containing the soluble scFv was purified by Ni-NTA agarose. 
100ml of the bacterial supernatant were incubated with 0.5ml Ni-NTA agarose 
(QUIAGEN, Hilden) at RT for 2h. The matrix was then washed with 50mM phosphate-
buffer pH=7.4 containing 500mM NaCl and  bound MAV was eluted with 1ml 0.5M 
imidazole in the same buffer.  
 
2.2.12 Western Blot 
For Western Blot analysis of the cell lysates, the cells from a 10 cm dish were lysed 
with 1 ml 2x Laemmli buffer [129], 10 µl of which were applied to SDS-PAGE. To 
analyse the proteins of the cell supernatant, 15 µl out of 5 ml were used. The samples 
were separated on 12.5% polyacrylamide gels for vIL-6, huIL-6 and MAV, and on 7.5% 
gels for STAT3 at 160 V. The protein transfer onto a PVDF membrane (Hybond-P, 
Amersham Bioscienes) was performed at 10 V for 1 h. The membrane was blocked in 
6% BSA/TBS at room temperature for 2 h followed by overnight incubation with the 
primary antibody diluted in 1% BSA/TBS-T at 4°C. After washing with TBS-T buffer, 
the membrane was incubated with the secondary POD conjugated antibody (Pierce) at 
room temperature for 1 h. After repeated washing with TBS-T and finally TBS the 
peroxidase substrate ECL(+) was applied (Amersham Biosciences). The enzymatic 
reaction caused chemiluminescence, so that the protein-antibody complex could be 
visualised on X-ray film.   
 
2.2.13 Immunoprecipitation of vIL-6 with MAV 
COS-7 cells were transiently transfected with p409-vIL-6. The next day, the DMEM 
medium containing 10%FCS was changed to 5 ml FCS-free DMEM. After 24h the 
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supernatant was removed and centrifuged at 10000g for 2min to remove cell debris. 1ml 
supernatant containing vIL-6 was incubated with 15µg of MAV at 4°C overnight under 
continuous rolling. Immunocomplexes were collected with 25µl Talon beads (Dynal) 
during incubation at 4°C for 2h. Unspecifically bound proteins were washed away with 
PBST and PBS buffers, before the MAV/vIL-6 complexes were eluted with 20µl 0.5M 
imidazole in PBS. The eluates were separated by SDS-polyacrylamide-gel-
electrophoresis and Western blot analysis was done using anti-vIL-6 serum as 
described.  
 
2.2.14 Proliferation assay 
 The neutralising assay was carried out with Baf/3-gp130 and Baf/3-gp130-IL-6R cells. 
Cultured cells (5 x 103/well of a 96-well microtiter plate) were washed three times with 
PBS. Thereafter, the cells were incubated in the presence of different concentrations of 
MAV (or without MAV as control) and a constant concentration of one of the following 
cytokines: vIL-6 (500 ng/ml), HIL-6 (1 ng/ml) or huIL-6 (1 ng/ml). After incubation for 
68h the cells were puls-labeled with 0.25 µCi [3H]thymidine for 4 h. Proliferation rates 
were measured by harvesting the cells on glass filters and determination of the 
incorporated radioactivity by scintillation counting. For each cytokine concentration the 
proliferation assay was performed at least three times in triplicates. 
 
2.2.15 Stimulation of HepG2 cells 
HepG2 cells were seeded out on 10 cm dishes to reach 70-80% confluency the next day. 
The cell growth medium containing 10%FCS was changed to FCS-free medium for 18 
h.  Subsequently, the cells were stimulated with 150 ng/ml recombinant vIL-6 alone or 
with MAV (150 ng/ml, 1.5 µg/ml, and 15 µg/ml) at 37°C and 5% CO2 for 10 min. After 
washing with PBS the cells were lysed in 1 ml 2xLaemmli and frozen down.  
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2.2.16 Analysis of STAT3 phosphorylation in human 
hepatoma cell line 
The lysates of the stimulated cells were subjected to 7.5% SDS-PAGE and the proteins 
transferred onto Hybond-P PVDF membrane (Amersham).  Phosphorylated STAT3 was 
detected in the Western blot (2.2.12) by an anti-phospho-STAT3 antibody (Biolabs). 
After 30 min incubation of the membrane in stripping buffer at 60°C, the total amount 
of STAT3 was analysed by Western blotting using an anti-STAT3 antibody (Biolabs). 
 
2.2.17 Surface Plasmon Resonance (SPR) 
2.2.17.1 Immobilisation of vIL-6 to the SPR sensorchip 
The SPR sensorchip (IAsys) was placed in the instrument and left with PBS-T for 45 
min to equilibrate. The cuvette was then washed with PBS-T three times for 5 min, 
before 0.2 M EDC/0.05 M NHS was added for 10 min to activate the chip. After 
another washing step with PBS-T to remove excess EDC/NHS, the buffer was changed 
to 10 mM Na-acetat pH=5.5 immobilisation buffer. Having recorded a stable baseline, 
40 µg recombinant vIL-6 were applied to the sensorchip. Non-coupled vIL-6 was 
removed by washing with PBS-T for 10 min and 1 M ethanolamine pH=8.5 was added 
for 2-3 min to block the free carboxyl groups of the dextran. The chip was washed again 
and could be used for the interaction analysis. 
2.2.17.2 Interaction analysis 
The binding experiment was performed at room temperature with different 
concentrations of MAV using the IAsys™ optical biosensor. Affinograms were 
analysed by nonlinear regression with the FASTfit software, which uses the Marguard-
Levenburg algorithm for iterative data fitting [131]. 
 
2.2.18 Immunostaining of transfected COS-7 cells 
Approximately 40.000 COS-7 cells grown on cover glasses for 24h were washed with 
PBS containing 0.1% acid and fixed with cold methanol at -20°C for 10min.  The cells 
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were then washed two times with TBS and incubated with blocking buffer (1%BSA, 
0.2% glycerine, TBS) at room temperature for 2h. A 1:100 dilution of the anti-myc 
antibody was applied at 4°C overnight. The cells were washed with TBS-T and TBS 
and incubated with the Alexa Fluor 594 anti-mouse antibody at 37°C for 1h. The 
washing was repeated as before and the cover glasses were mounted on slides with 
SlowFade Light (Molecular Probes, USA) and analysed using fluorescence microscopy. 
A 543-fold magnification was used to photograph the cells. 
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3 Results 
 
3.1 Expression of recombinant vIL-6 
3.1.1 Expression of recombinant vIL-6 in bacteria 
About 7 mg of recombinant viral IL-6 were required as antigen for phage panning 
and immunological characterisation of selected antibodies. Viral IL-6 was first expressed as 
a fusion protein containing 6xhis residues as a C-terminal tag in the E. coli pET-expression 
system (Novagen). pET vectors are one of the the most powerful systems for high bacterial 
expression of recombinant proteins [132, 133]. 
The vIL-6 cDNA sequence was amplified by PCR using the primers KJ1601 and 
KJ1701, before cloning into the his-tag containing vector pET16b opened by BamHI and 
NdeI (Fig. 3.1.1). To verify the vIL-6 sequence (see appendix) and the ORF, the construct  
KJ1601     5‘ -GGG AAT TCC ATA TGT TGC CGG ACG CCC CCG AG -3‘
KJ1701     5‘ -CGC GGA TCC TCA CTT ATC GTG GAC GTC AG -3‘
A
B
 
Fig. 3.1.1 Vector map of pET16b-vIL-6-his: A Sequence of the primers used for vIL-6 amplification; 
B Amplified vIL-6 was cloned into pET16b plasmid vector opened by BamHI and NdeI. Amp- 
ampicillin resistance gene, T7 – T7 promoter, 6xhis- histidin tag sequence. 
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was sequenced using the same primers as for the amplification. The expression of vIL-6 upon 
IPTG induction was successful in the bacterial strain BL21plysS but not in E. coli BL21 (Fig. 
3.1.2 A). Bacterial cells containing the plasmid pLysS produce T7 lysozyme, which is a 
natural inhibitor of T7 RNA polymerase and thus reduces the transcription of the target gene 
in uninduced cells. The expression of the protein prior induction might be harmful for the 
bacteria. The bacterial culture was grown under inducing conditions for 4h. After collecting 
the bacteria by centrifugation, they were lysed using the French Press. Subsequently, the 
bacterial products accumulated in the cytoplasm in soluble form or as insoluble inclusion 
bodies were separated by high speed centrifugation. The recombinant vIL-6 was located in 
inclusion bodies (Fig. 3.1.2 B), which were resolved in 6 M guanidine hydrochloride and 
 
116
66
45
35
25
18
14
his-vIL-6
BL21 BL21 plysS BL21 BL21 plysS
IPTG:
- - - -+ + + +
10µl 100µl
1      2
A B
 
Fig. 3.1.2 Bacterial expression of recombinant vIL-6: A SDS-PAGE of E. coli BL21/BL21plysS cells from 10 
µl and 100 µl bacterial culture. IPTG induced expression of vIL-6 was obtained only with bacterial strain 
BL21plysS. B Coomassie staining of soluble (lane 1) and insoluble (lane 2) proteins expressed in bacteria. 
Bacterial cells were lysed by sonication. vIL-6 was expressed in inclusion bodies (lane 2). 
 
loaded onto a Ni-NTA spin column (Amersham). The purification was accomplished via 
binding of the his-tag of vIL-6 to the Ni2+ of the column’s matrix (Fig 3.1.3). Unbound 
proteins were removed by washing with guanidine hydrochloride-containing buffer. After 
washing with guanidine hydrochloride-free buffer, the bound recombinant vIL-6 was eluted 
from the Ni-matrix with 0.5 M imidazole. This way, the vIL-6 was refolded directly on the 
column. The eluted protein was dialyzed against Tris-buffer. To analyse its molecular mass 
and purity it was applied to an SDS polyacrylamide gel (Fig. 3.1.4A). The recombinant vIL-6 
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preparation was additionally checked by Western blot analysis using an anti-vIL-6 serum 
[69] (Fig. 3.1.4 B). 
 
Fig. 3.1.3 Binding of the polyhistidine-tagged vIL-6 to Ni-NTA-agarose (schematic illustration): A Ni 
resin; a matrix bead bearing the pentadentate metal chelator with bound Ni2+ ion; B One histidine residue of the 
polyhistidine-tag of the recombinant protein binds to the resin. 
 
25
18
14
35
66
116
his-vIL-6
A B
vIL-6M vIL-6
 
Fig. 3.1.4 Purification of recombinant vIL-6 protein: His-vIL-6 was purified from inclusion bodies dissolved 
in 6 M guanidinhydrochloride by Ni-NTA-agarose. A Coomassie staining of purified protein, M- protein 
marker, vIL-6- purified recombinant viral IL-6; B Western Blot using anti-vIL-6-serum (1:10000). 
 
 
The bioactivity of the expressed and purified vIL-6 was measured using Baf/3 cells 
stably transfected with gp130. Baf/3 cells are murine IL-3 dependent pro-B-cells, which do 
not express receptors of the IL-6 cytokine family [127, 128]. In the absence of IL-3, Baf/3 
cells transfected with the gp130 receptor cDNA proliferate after stimulation by vIL-6 as well 
as Hyper-IL-6 (see introduction) [72, 96]. In proliferation assays performed to test the 
activity of recombinant vIL-6, Baf/3-gp130 cells were stimulated with different 
concentrations of the viral cytokine and with Hyper-IL-6 as positive control. Unfortunately, 
the result was not consistent. In some experiments the vIL-6 seemed to be functional. But in  
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Fig. 3.1.5. Biological activity of recombinant vIL-6: Baf/3-gp130 cells were stimulated to grow by 
increasing amounts of Hyper-IL-6 and purified recombinant vIL-6. Proliferation of cells was assessed 
by measuring of [3H]thymidine incorporation into DNA. 
 
most experiments it was clearly inactive (Fig. 3.1.5). Therefore, as an alternative, secreted 
eukaryotic expression of vIL-6 was explored in COS-7 cells. Viral IL-6 carrying the N-
terminal signal peptide was synthesised at the ribosomes of the endoplasmic reticulum, 
transported to the cell membrane and released. The expression in eukaryotic cells supported 
the folding and posttranslational modification of vIL-6, resulting in secretion of biologically 
active vIL-6 [72, 135].   
. 
3.1.2 Eukaryotic expression of vIL-6 
The COS-7 cell (African Green Monkey kidney fibroblast cells) expression system 
achieves high-level, transient expression of proteins. These cells express the SV40 large 
tumor antigen, which is necessary to initiate DNA replication at the SV40 origin. A high 
copy number of plasmids containing an SV40-drived origin of replication is present in COS-
7 cells 48h post-transfection. If the transfected DNA encodes a secretion protein, up to 10 µg 
of protein per 107 cells can be recovered from the supernatant of the transfected COS-7 cells 
after one week post-transfection [72, 136]. 
COS-7 cells were transiently transfected [137] with the expression plasmid p409-
vIL-6-his [72]. The recombinant protein was collected in the cell medium containing 0.5% 
FCS over 7 days and purified by Ni-NTA-agarose. 100 ml medium were incubated with 0.5 
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ml Ni-NTA-agarose, followed by washing with PBS and elution of vIL-6-his from the 
matrix with 0.5 M imidazole. The purity of the vIL-6 was analysed by SDS-PAGE and 
subsequent silverstaining (Fig. 3.1.6).  
Also, EBNA-293 cells stably transfected with vIL-6 were obtained in collaboration 
with Jutta Eichler (GBF, Braunschweig). The modular episomal vector pCEP-Pu [138], 
based on the Epstein-Barr virus genome, was used as an expression system for vIL-6 (Fig. 
3.1.7). Two genetic elements, the viral origin of replication and the gene for nuclear antigen  
 
 
vIL-6-his
 
 
 
 
 
 
 
 
Fig. 3.1.6 Expression of vIL-6 in 
eukaryotic cells: Silverstaining of 
vIL-6 with C-terminal his-tag 
expressed in COS-7 cells and 
purified by affinity chromatography 
using Ni-NTA-agarose.  
 
 
BM-40 signalpeptid his-tag vIL-6~700bp
BM-40 signalpeptid flag-tag vIL-6~700bp his-tag
 
Fig. 3.1.7 vIL-6 expression cassettes for EBNA-293 expression: Schematic map of the expression 
constructs pCEP-Pu-flag-vIL-6-his and pCEP-Pu-his-vIL-6. P CMV- cytomegalovirus promoter; Ori 
P- EBV (Epstein Barr Virus) origin of replication; EBNA-1- gene 1 of the Epstein Barr Virus; colE1 
ori- colE1 origin of replication; PSV40- SV40 promoter; SV40pA- SV40 poly-A. 
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EBNA-1, are necessary to sustain high-copy-number episomal replication of recombinant 
vectors in cells [139]. The expression constructs contained the vIL-6 sequence with an N-
terminal his-tag and vIL-6 with two affinity tags, an N-terminal flag-tag and a C-terminal 
his-tag (see appendix).  
The EBNA-293 cells were cultured under the same conditions as the COS-7 cells. 
After 7 days the supernatant of stably transfected cells was analysed for vIL-6 expression. 1 
µl of the medium from each cell line was applied to a 12.5% SDS-PAGE, blotted onto a 
PVDF membrane and stained by anti-vIL-6-serum [69].  Interestingly, the expression of flag-
vIL-6-his in EBNA-293 cells was much higher than that of his-vIL-6 in COS-7 or EBNA-
293 cells (Fig. 3.1.8). Because both recombinant proteins expressed in EBNA-293 cells 
contained a his-tag, they were purified by Ni-NTA-agarose. The successful purification of 
the EBNA-293 cell expressed proteins was shown by SDS-PAGE and Western blot using the 
anti-vIL-6-serum (Fig. 3.1.9 A, B, C).  
 
46
31
24
1            2             3            4
recombinant
vIL-6
COS-7 EBNA
 
Fig. 3.1.8 Expression of vIL-6 in eukaryotic cells: Comparison of vIL-6 expression in COS-7 cells 
and EBNA-293 cells. 2 µl of cell growth medium were applied onto the SDS-polyacrylamide gel. 
Western blot with anti-vIL-6-serum was done: lane 1- COS-7 cells transiently transfected with vIL-6-
his; lane 2- untransfected COS-7; lane 3- EBNA-293 cells stably transfected with vIL-6-his; lane 4- 
EBNA-293 cells stably transfected with flag-vIL-6-his. 
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Fig. 3.1.9 Purification of vIL-6 expressed by EBNA-293 cells: Silverstaining of his-vIL-6 (A) and 
flag-vIL-6-his (B) purified by Ni-NTA-agarose. C Western blot of recombinant flag-vIL-6-his (15 ng, 
1.5 ng) and his-vIL-6 (50 ng, 5 ng). Viral IL-6 was detected using rabbit anti-vIL-6-serum diluted 
1:10000.  
 
To control the correct folding of the recombinant vIL-6 proteins, circular dichroism 
(CD) spectra were recorded. As other cytokines of the IL-6 cytokine family, correctly folded 
vIL-6 has a four helical bundle structure [68]. vIL-6 expressed and purified from EBNA-293 
cells displayed a typical α-helical spectrum. His-vIL-6 displayed an even more helical 
spectrum than the flag-tagged one (Fig. 3.1.10). The CD-spectrum of the bacterial expressed 
vIL-6 reflects a helical structure of the protein, too, but differences in folding of the 
eukaryotic and the bacterial expressed proteins are obvious (Fig. 3.1.10). This suggests that 
high amounts of bacterial expressed vIL-6 were not folded, and that most molecules of the 
recombinant protein remained unstructured. Such CD-spectra have been observed for higher 
order structures such as aggregates and oligomers [140].  
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Fig. 3.1.10 Circular dichroism spectra: α-helical fold of flag-vIL-6-his (blue) and vIL-6-his (red) 
expressed by and purified from EBNA-293 cells and of vIL-6-his expressed in bacterial cells (black). 
 
 
Baf/3-gp130
10-2 10-1 100 101 102 103 104
0
25000
50000
75000 H-IL-6
flag-vIL-6-his (EBNA)
his-vIL-6 (EBNA)
his-vIL-6 (bac.exp.)
concentration, ng/ml
 
Fig. 3.1.11 Induction of proliferation of Baf/3-gp130 cells by vIL-6: Baf/3-gp130 cells were 
stimulated with increasing amounts of EBNA-293-expressed flag-vIL-6-his or his-vIL-6 or bacterial 
expressed vIL-6-his or Hyper-IL-6.  Proliferation was measured by [3H]thymidine incorporation.  
 
To test for biological activity of EBNA-293 expressed vIL-6, the same proliferation 
assay was used as for recombinant vIL-6 expressed in bacterial cells. Previous studies had 
shown that Baf/3-gp130 cells are able to proliferate in response to Hyper-IL-6 at a 
concentration below 1 ng/ml, whereas 100 ng/ml of viral IL-6 were needed to induce Baf/3-
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gp130 cell proliferation [69, 72]. The concentration of vIL-6 proteins was determined 
photometrically at 240-320nm using the method of Waxman [141]. In this study, flag-vIL-6 
and his-vIL-6 expressed in EBNA-293 cells induced proliferation of Baf/3-gp130 cells at 
similar concentrations (Fig. 3.1.11).  
Interestingly, in EBNA-293 cells, the expression level of flag-vIL-6-his was three-
fold higher than the one of his-vIL-6: About 100 µg were obtained after purification of 100 
ml conditioned cell medium (7 days) from flag-vIL-6-his transfected EBNA-293 cells, and 
only 20-30 µg from 100 ml conditioned medium (7 days) of his-vIL-6 transfected EBNA-
293 cells. Thus, flag-vIL-6-his was produced in large enough amounts to be used as coating 
antigen for the phage display. 
 
3.2 Production of recombinant antibodies against vIL-6 
3.2.1 Phage library screening 
For the production of recombinant antibodies against vIL-6 the phage display 
technology was chosen [142]. The main advantage of this method over the hybridoma 
technology is the possibility to obtain human antibodies from an antibody library within a 
few weeks. To isolate gene sequences coding for anti-vIL-6 scFv, the libraries Tomlinson A 
and B (Tomlinson, T., MRC, Centre for Protein Engineering, Cambridge, UK), each 
comprising 109 scFv fragments (IPK Gatersleben, Germany), were screened using  
 
Fig. 3.2.1 Vector map of pIT-scFv: VH- variable region of the heavy chain of human IgG; VL- 
variable region of the light chain of human IgG; myc-tag- myc-tag sequence; amber- stop-codon; pIII- 
phage cover protein; M13 ori- phage M13 origin of replication; amp- ampicillin resistance gene; colE1 
ori- colE1 origin of replication; lac promoter- lacZ promoter; RBS- ribosome binding site; pelB leader 
– signal peptide for periplasmic expression. 
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recombinant flag-vIL-6-his as coating antigen for phage panning. Both libraries are based on 
a single human framework for the variable regions of heavy (VH) and light (VL) human 
immunoglobulin chains. Artificial scFvs were genetically engineered by random 
combination of cDNA fragments encoding hypervariable regions (CDRs) of heavy and light 
variable chains connected by a short glycine-serine linker and cloned into phagemid pIT1  
[143, 144]. The phagemid pIT1-scFv encodes the scFv gene fused in-frame with the phage 
gene coding for the phage surface protein pIII (Fig. 3.2.1). The scFv antibodies were 
displayed on the phage surface during the phage life cycle, achieved by co-transfection of the 
bacterial cells E. coli TG1 with pIT1-scFv and the wild type phage (Fig. 3.2.2).  
 
pIT1 with Antibody Genes
pIIIAb-gene
wild type
phage
A B
phage-
antibody
 
Fig. 3.2.2 Presentation of antibody fragments on the surface of filamentous phage: Antibody 
fragments (brown) are presented on the phage surface as a fusion with phage protein pIII (blue). A 
Scheme of the structure of a “phage-antibody”; B Production of phage-antibodies during phage life 
cycle via co-transfection of bacterial cells with a phagemide. 
 
The antigen-specific phage selection procedure, also called biopanning, relies on the 
highly specific binding of phage particles from the library to the antigen coated on the solid 
phase, in this case vIL-6. After panning, non-bound particles were eliminated by washing, 
and the phages bound to vIL-6 were eluted and amplified by infection of bacterial cells E. 
coli TG1 (Fig. 3.2.3). The obtained phage particles were precipitated from the culture 
supernatant and subjected to the next round of selection. This process had to be repeated 
three times, because the pool of phages obtained in the first round of selection displayed 
scFvs with various affinities and specificities to the antigen. The second panning was 
performed to enrich the phage pool for phages displaying anti-vIL-6 scFvs with high  
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Fig. 3.2.3 Schematic illustration of one round of biopanning: Specific phages bind to immobilised antigen 
and non-specific phages are washed away. Antigen-bound phages can be eluted and amplified by infection of 
the bacteria. 
 
antigenic specificity and affinity. In the third round, the phage pool was divided into single 
phage clones. 200 of the phage clones were infected into the bacterial cells E. coli HB2151 
for production of soluble scFvs. The pIT1-scFv phagemid encodes the gene of scFv fused to 
the gene of the phage surface protein pIII. Between these genes a stop-codon is placed, 
which in the bacterial suppressor strain E. coli TG1 is translated into an amino acid.  HB2151 
is a non-suppressor strain of the bacteria. In the bacterial cells E. coli HB2151, the 
transcription terminated after the stop-codon, leading to the expression of soluble antibody 
fragments without the pIII portion (Fig. 3.2.4 A). The expression of the scFvs under the lac-
promoter was induced by IPTG. The signal peptide of pectate lyase B (pelB) is responsible 
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for the secretion of the expressed protein into the periplasmic space (that is the space 
between the inner and outer membrane) of the gram-negative bacteria. The ability of soluble 
scFv to recognise recombinant vIL-6 was verified by ELISA. The principle of the scFv 
ELISA is schematically demonstrated in Fig. 3.2.4 B. Soluble scFvs from individual phage 
clones were used as primary antibodies to bind to the immobilised recombinant vIL-6. The 
scFvs bound to the  
Ag: vIL-6
scFv with myc-tag
AP-anti-mouse-Ab
anti-myc-Ab
pIIIAb-gene
pIIIAb-gene
stop
TG1
(UAG suppressor strain)
HB2151
(non-suppressor strain)
A B
 
Fig. 3.2.4 Production and detection of the soluble antibody fragments: A Soluble antibodies were produced 
by retransfection of the phagemide into the non-suppressor bacterial strain HB2151. B Scheme of scFv ELISA: 
Ag: vIL-6- solid fixed recombinant flag-vIL-6-his as coating antigen; scFv with myc-tag- soluble anti-vIL-6 
scFv with myc-tag; anti-myc-Ab- anti-myc antibody 9E10 recognised myc-tag of the scFv; AP-anti-mouse-Ab- 
anti-mouse-IgG antibody conjugated to alkaline phosphatase to detect bound monoclonal anti-myc antibody. 
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Fig. 3.2.5 Soluble scFv ELISA: Detection of the vIL-6 specific scFvs after 3rd round of panning. A 
Library Tomlinson A. B Library Tomlinson B. A12, B12 and I12, J12 are positive controls: scFv 
against plant transcription factor ABI3/7 (IPK Gatersleben) specifically binds to ABI3/7. C12, D12 
and K12, L12 are negative controls with BSA.   
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antigen were specifically recognised by the monoclonal anti-myc-antibody 9E10 followed by 
an anti-mouse IgG conjugated to alkaline phosphatase (AP). Using the AP-substrate 4-
nitrophenyl phosphate, the extinction of the reaction product at 405 nm was a measure for 
AP activity. As can be seen in Fig. 3.2.5, seven clones seemed to be positive. 
The cDNA sequence of each of these seven clones was analysed by PCR using the 
phagemide primers LMB3 and pHEN. The 908 bp DNA fragment coding for the scFv was 
obtained for five clones (Fig. 3.2.6). Clones 1 and 4 contained only the variable heavy chain 
corresponding to the size of about 600 bp. However, such a result was not unexpected, since 
previous studies had shown that incomplete clones are present in the Tomlinson library [145, 
146].  
VH+VL
VH
1000
500
bp
1     2     3     4      5      6     7 
LMB3  5‘- CAG GAA ACA GCT ATG AC -3‘
pHEN 5‘- CTA TGC GGC CCC ATT CA -3‘ 
 
Fig. 3.2.6 PCR of human recombinant antibodies scFv screened against vIL-6: PCR of 7 
individual phage clones was prepared by phagemid primers LMB3 and pHEN. VH+VL- full sequence 
of scFv (heavy and light chains); VH- scFv containing only heavy chain. 
 
1      2      3      4       5       6      7 
flag-vIL-6-his
hu-IL-6
his-OSM
BSA
ABI3/7
 
Fig. 3.2.7 Cross-reactivity of scFv screened against vIL-6: The specificity of screened recombinant 
antibodies was analysed by ELISA with different antigens such as human IL-6 (huIL-6), his-OSM 
(oncostatin M), BSA, ABI3/7 (plant transcription factor). Only one clone of scFv (7, later MAV1) was 
really specific for vIL-6. 
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To analyse the specificity of the screened scFvs for vIL-6, they were tested for cross-
reactivity with other antigens by ELISA. Unspecific scFvs were those antibody fragments, 
which did not bind to vIL-6 only, but to other antigens, too. Five clones from seven displayed 
very little and unspecific binding. Clone 2 exhibited some cross-reactivity with his-OSM and 
BSA and very strong cross-reactivity with human IL-6. Only clone 7 (later MAV1) was 
highly specific for vIL-6 (Fig. 3.2.7). Therefore, clones 1-6 were not further analysed. 
However, since in previous studies using different antibody libraries and antigens 
more than one specific antibody could be selected [119, 147], we assumed that we similarly 
would be able to isolate more scFvs specific for vIL-6. Therefore, further 200 phage clones 
were analysed for displaying scFvs specific for vIL-6. In the same way as the 200 clones 
tested before, the 200 new phage clones were retransfected into the non-suppressor bacterial 
cells HB2151 to produce soluble scFv. Soluble scFv from individual phage clones were 
analysed by ELISA for binding to vIL-6 (date not shown). Again, only one recombinant 
antibody with high specificity to vIL-6 was found (later called MAV2). The cross-reactivity 
of MAV2 with other antigenes was tested by ELISA in comparison to MAV1 (Fig. 3.2.8). 
MAV2 as well as MAV1 did not display any cross-reactivity and showed specific binding 
for flag-vIL-6-his and his-vIL-6. The detected weak binding of both antibodies to gp130-Fc 
was probably unspecific. Most likely, the secondary AP-anti-mouse antibody recognised the 
Fc part of gp130-Fc (Fig. 3.2.8). 
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Fig. 3.2.8 Cross-reactivity of scFv screened against vIL-6: 200 new clones of scFv were screened and one 
positive was found (MAV2). Its specificity was analysed by ELISA with different antigens such as BSA, 
lysozym, human IL-6 (huIL-6), his-OSM (oncostatin M), gp130-Fc, ABI3/7 (plant transctiption factor) and 
compared to MAV1.   
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3.2.2 Western blot and sequence analysis of screened scFvs 
The expression of MAV1 and MAV2 in E. coli HB2151 was analysed by Western 
blotting using an anti-myc antibody as a secondary antibody that recognised the C-terminal 
myc-tag of the scFv. Bacterial cells E. coli HB2151 were infected with the phages containing 
phagemids pIT1-MAV1 and pIT1-MAV2 or were not infected and grown in medium with 
low amounts of glucose in order to down-regulate transcription of the phage genes. The 
glucose was metabolised by the time IPTG was added to induce the expression of scFvs. The 
secreted recombinant antibody fragments were directly detected in samples of the culture 
medium. The 30 kDa bands seen in the Western blot of the medium from infected bacteria 
correspond to MAV1 and MAV2 (Fig. 3.2.9). 
10µl 10 µl 1 µl 0.1 µl     10 µl 1 µl 0.1 µl
33
26
20
kDa
MAV1 MAV2
product of 
degradation?
 
Fig. 3.2.9 Expression of MAV in HB2151 bacterial cells: Western blot of medium from HB2151 cells 
infected with phages and expressing MAV1 or MAV2 (first lane: medium from non-infected cells). 10µl, 1 µl 
and 0,1 µl of medium were applied to SDS-PAGE, blotted and the scFv expression was detected by anti-myc 
antibody 9E10 (1:50).  
 
To characterise the cDNA sequence of MAV1 and MAV2, pIT1-MAV1 and pIT1-
MAV2 phagemids were isolated from an infected E. coli HB2151 bacterial cell culture 
grown in low-glucose-medium. The DNA-sequence encoding the scFv was verified by 
sequencing (HotShot sequencing, SEQLAB, Goettingen) with the primers LBM3 and pHEN 
(Fig. 3.2.6). The translated amino acid sequence alignment is shown in Fig. 3.2.10 (for DNA 
sequence see appendix). Surprisingly, the sequence of MAV1 was identical to the one of 
MAV2, suggesting that in the course of two different selection procedures the same antibody 
fragment (MAV) has been isolated. This may indicate that no additional scFvs specific for 
vIL-6 are present in the library. 
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1 XASLHANSISRKTVI MKYLLPTAAAGLLLL AAQPAMAEVQLLESG GGLVQPGGSLRLSCA ASGFTFSSYAMSWVR QAPGKGLEWVSDIRG 90
2 XXQLACKFYFKETVI MKYLLPTAAAGLLLL AAQPAMAEVQLLESG GGLVQPGGSLRLSCA ASGFTFSSYAMSWVR QAPGKGLEWVSDIRG 90
1 RGPPTGYADSVKGRF TISRDNSKNTLYLQM NSLRAEDTAVYYCAK RMWGFDYWGQGTLVT VSSGGGGSGGGGSGG GGSTDIQMTQSPSSL    180
2 RGPPTGYADSVKGRF TISRDNSKNTLYLQM NSLRAEDTAVYYCAK RMWGFDYWGQGTLVT VSSGGGGSGGGGSGG GGSTDIQMTQSPSSL    180
1 SASVGDRVTITCRAS QSISSYLNWYQQKPG KAPKLLIYGASRLQS GVPSRFSGSGSGTDF TLTISSLQPEDFATY YCQQAWHLPLTFGQG    270
2 SASVGDRVTITCRAS QSISSYLNWYQQKPG KAPKLLIYGASRLQS GVPSRFSGSGSGTDF TLTISSLQPEDFATY YCQQAWHLPLTFGQG    270
1 TKVEIKRAAAEQKLI SEE    288
2 TKVEIKRAAAEQKLI SEE    288
CDR I CDR II
CDR III
CDR I CDR II CDR III
linker
VH
VL
 
Fig. 3.2.10 Protein Alignment: MAV1 (1) and MAV2 (2) sequences. VH- variable region of the heavy chain 
of human IgG; VL- variable region of the light chain of human IgG; CDR- hypervariable region (blue- 
specific for MAV amino  acids compared to other scFv of Tomlinson library); linker (red)- glycin/serin 
linker.  
 
3.2.3 Production and purification of large amounts of MAV 
The pET-vector-system (Novagen), which was used for the bacterial expression of 
vIL-6, was chosen for the expression of the recombinant antibody. The MAV coding 
sequence was cut out from pIT1 by NcoI and NotI (Fig. 3.2.1) and inserted into the pET22b 
vector via NcoI and NotI. pET22b ensures the expression of the gene of interest in soluble 
form in the periplasmic space due to the pelB leader sequence, which encodes a signal 
peptide for periplasmic expression. The antibody sequence together with the pelB leader was 
recloned into the vector pET23a by XbaI and NotI, so that MAV obtained a his- and myc-tag, 
which are missing in pET22b. The tags are helpful for detection and purification of the 
recombinant scFv. The map of the expression construct pET23a-MAV is depicted in Fig. 
3.2.11.   
The expression of MAV induced by IPTG was detectable in the supernatant of E. coli 
BL21 as well as BL21plysS transformed with pET23a-MAV cDNA (Fig. 3.2.12 A). 2µl of the 
supernatant of the bacterial culture, either induced or not induced for expression, were  
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Fig. 3.2.11 MAV-expression plasmid for bacterial transformation: MAV- recombinant antibody 
sequence; amp- ampicillin resistance gene; lac promoter- lacZ promoter; RBS- ribosome binding site; 
pelB leader- signalpeptide for periplasmic expression. 
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Fig. 3.2.12 Expression of pET23b-MAV in E.coli strains BL21 and BL21plysS: Periplasmic 
expression of MAV was induced by IPTG stimulation. After centrifuging, cell medium was 
electrophoretically separated on a 12.5% polyacrylamide gel. A Dependency of  MAV expression level 
in E. coli BL21 on the expression time, silverstaining of bacterial supernatant (15 µl in each lane) 
before IPTG induction and after 0.5, 1, 2, 3, 4,  6 hours and overnight expression. B Western blot 
analysis of MAV expression in E. coli BL21; C Western blot of MAV expression in E. coli BL21plysS 
using anti-myc antibody. 
 
applied to a 12.5%polyacrylamide gel and blotted onto a PVDF membrane. An anti-myc 
antibody recognised expressed MAV (30 kDa) via its C-terminal myc-tag in the Western 
Blot (Fig. 3.2.12 B and C). The 18 kDa band could be the variable region of the light chain 
(VL) including the myc- and his-tags generated by limited proteolytical degradation of scFv 
molecules during expression. 
Like the recombinant vIL-6, MAV was purified using Ni-NTA-agarose. The bacterial 
culture was centrifuged and the supernatant incubated with Ni-agarose beads. MAV bound 
to the Ni2+ of the matrix via its his-tag. Unbound proteins were washed away and MAV was 
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eluted with buffer containing 0.5 M imidazole. The quality of the purification was analysed 
by SDS-PAGE (Fig. 3.2.13). The VL part of MAV seen in the Western blot (Fig. 3.2.12 B 
and C) seemed to co-purify via the his-tag. 
 
35
25
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200ng       100ng      50ng
MAV
VL of MAV
 
Fig. 3.2.13 Purification of MAV: MAV was expressed in the periplasmic space of the bacteria and 
purified by Ni-NTA-agarose. Pure protein was separated by a 12.5% SDS-PAGE and visualised by 
silverstaining. 
 
3.2.4 Properties of MAV 
3.2.4.1 MAV recognition of vIL-6 in ELISA and Western 
blot 
The purified recombinant antibody fragment MAV was analysed by ELISA for 
specific binding to vIL-6. Different antigens were coated at a concentration of 10 µg/ml and 
0.5 µg MAV per well were added. Binding of MAV to vIL-6 was detected by an anti-myc 
antibody. MAV bound to flag-vIL-6-his and his-vIL-6, but did not exhibit any cross-
reactivity with other antigens such as huIL-6, his-tagged OSM, BSA, lysozym, ABI 3/7 and 
gp130-Fc (Fig. 3.2.14). Because flag-vIL-6-his was used as coating antigen for the panning, 
it was important to test the MAV specificity for the flag- and his-tag. Specific binding of 
MAV to his-vIL-6 suggested that MAV did not recognise the flag-tag. However, the flag-tag 
could have an effect on the binding affinity of MAV to vIL-6 (compare flag-vIL-6-his and 
his-vIL-6 in Fig. 3.2.14). Also, the lack of binding to the his-tagged OSM suggested there 
was no cross-reactivity with the his-tag.   
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MAV binding to vIL-6 was also shown by Western blotting. MAV was used as a 
primary antibody recognising vIL-6, which was applied to a 12.5% SDS-PAGE and 
transferred onto a PVDF membrane. 100 ng of vIL-6 protein could be detected by MAV 
under these conditions (Fig. 3.2.15). It is concluded that MAV recognised native and 
denaturated vIL-6 protein. 
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Fig. 3.2.14 Specific recognition of vIL-6 by MAV: MAV specific binding to flag-vIL-6-his and his-
vIL-6, but not to human IL-6 or other antigens was demonstrated by ELISA.  
 
flag-vIL-6-his
1µg 100ng     10ng
 
Fig. 3.2.15 MAV-recognition of vIL-6 by Western Blot:  1µg, 100ng, 10ng of recombinant vIL-6 
was separated on 12.5% SDS-PAGE, blotted and detected by MAV as primary antibody. As secondary 
antibody anti myc-antibody 9E10 (1:50) was used.  
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3.2.4.2 Binding of MAV to vIL-6 in solution: 
immunoprecipitation of vIL-6 with MAV 
It was shown that MAV recognises vIL-6 in the Western blot and also specifically 
binds to immobilised vIL-6 in the ELISA. The next step was to investigate whether MAV 
binds to vIL-6 in solution. Therefore, COS-7 cells were transiently transfected with an 
expression plasmid encoding vIL-6, and the supernatant of transfected as well as 
untransfected cells (negative control) was incubated with MAV. Histidine-tagged MAV 
could then be isolated by cobalt-based metal affinity chromatography using Talon dynabeads 
(Dynal). vIL-6 bound to MAV was co-precipitated with MAV. Elution of MAV or MAV 
with bound vIL-6 from the beads was done with 0.5 M imidazole. The presence of vIL-6 in 
the eluates was monitored by Western blotting using anti-vIL-6-serum. The fact that vIL-6 
was precipitated with MAV suggested that vIL-6 can bind to MAV in solution. 15 µl 
supernatant of transfected or untransfected cells were directly applied to SDS-PAGE and 
blotted as a control for the successful transfection (Fig. 3.2.16). 
20
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Fig. 3.2.16 Binding of MAV to recombinant vIL-6 in solution: supernatants of COS-7 cells 
transfected with vIL-6 or untransfected were directly applied to SDS-PAGE (first and second lane) or 
used for immunoprecipitation with MAV. His-tagged MAV and vIL-6 bound to MAV were isolated by 
Talon and than separated on a 12.5% polyacrylamide gel. Western blot was done using an anti-vIL-6 
serum [69]. Detection of unglycosylated as well as glycosylated vIL-6 protein in the supernatant of 
transfected COS-7 cells was previously described [74, 171]. 
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3.2.4.3 Epitope mapping: binding site of vIL-6 to MAV 
To identify the epitope of vIL-6 which is recognised by MAV, several chimeras of 
human and viral IL-6 were produced (Rabe B., unpublished). huIL-6 as well as vIL-6 has a 
four-helical (ABCD) structure [65]. Gp130 receptor binding sites of these cytokines are 
defined as sites II, composed of helix A and C, and III, consisting of the initial part of the 
AB-loop and helix D. The chimeras represent the huIL-6 sequence with the exchange of site 
II and III of vIL-6 (Fig. 3.2.17 A). Because MAV specifically binds to vIL-6 but not to huIL-
6, these chimeras can be used to define which region of vIL-6 is recognised by MAV [148, 
149]. The chimeric proteins were separated by SDS-PAGE and blotted onto a membrane 
which then was incubated with MAV. MAV bound to vIL-6 or the chimera was detected by 
an anti-myc antibody. As shown in figure 3.2.17 B, MAV bound to vIL-6 and the chimera 
II+III, which has the complete receptor binding sites II and III of vIL-6. Because MAV did 
not bind to the chimeras A, C, and A+C, one can conclude that the binding epitope of vIL-6 
to MAV is not on site II. MAV binding to chimera II+III suggests that site III of vIL-6 can 
be the recognition site for MAV. However, the AB-loop of site III does not seem to be 
involved in the binding of MAV, because MAV does not bind to the AB chimera. Therefore,  
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Fig. 3.2.17 Mapping of the vIL-6 epitopes recognised by MAV: A Schematic illustration of human 
(yellow)/viral (green) IL-6 chimeras. Chimera A has A-helix of vIL-6, chimera C- C-helix, chimera 
A+C - both helixes A and C of vIL-6, AB- AB-loop of vIL-6, chimera II+III- complete sites II and III 
of vIL-6. B 1µg vIL-6, huIL-6 or v/huIL-6-chimeras were separated by SDS-PAGE, immunoblotted 
with MAV and detected with anti-myc antibody 9E10.  
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we assume that the D-helix of site III of vIL-6 is necessary for recognition by MAV. 
Unfortunately, it was not possible to confirm this result using a huIL-6 chimera containing 
the vIL-6 D-helix because this chimera could not be expressed in bacteria so far (Rabe, B., 
unpublished).  
The same results were obtained when the chimeras were analysed by ELISA (Fig. 
3.2.18): MAV bound to vIL-6 and to the chimera II+III, which is huIL-6 with the complete 
exchange of site II and III of vIL-6, but not to the other chimeras. 
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Fig. 3.2.18 Mapping of the vIL-6 epitopes recognised by MAV:  vIL-6, huIL-6 or v/huIL-6-
chimeras (10µg/ml) were coated on the plate and ELISA was performed using MAV (5µg/ml). 
 
3.2.4.4 “Sandwich” ELISA 
It is known that vIL-6 binds to sgp130 [72]. In this study, flag-vIL-6-his bound to sgp130-
Fc was detected by an anti-flag antibody in the ELISA (Fig.3.2.19 B). To answer the 
question whether MAV binds to vIL-6 which has already bound to sgp130-Fc, a 
“sandwich” ELISA was performed (Fig. 3.2.19 A). Sgp130-Fc was the coating antigen; 
vIL-6 and then MAV were added. vIL-6 bound to sgp130 should bind to MAV, if the 
MAV binding epitope on vIL-6 is accessible. MAV bound to vIL-6 was detected by a 
mouse anti-myc antibody followed by an AP-anti-mouse antibody. Figure 3.2.19 C shows 
the result of the “sandwich” ELISA. Because vIL-6 bound to sgp130-Fc was not detected 
by MAV any more, sgp130-Fc and MAV seem to have an overlapping binding site on vIL-
6, which most likely is the gp130-binding site III. 
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Fig. 3.2.19 A Scheme of “Sandwich” ELISA: gp130Fc- solid fixed recombinant gp130Fc; Ag: vIL-
6- recombinant flag-vIL-6-his; MAV with myc-tag- soluble anti-vIL-6 scFv MAV with myc-tag; anti-
myc-Ab- anti-myc antibody 9E10 recognising myc-tag of MAV; AP-anti-mouse-Ab- anti-mouse-IgG 
antibody conjugated to alkaline phosphatase to detect bound monoclonal anti-myc antibody. B vIL-6 
binding to sgp130 in ELISA: sgp130 was the coating antigen and increased concentrations of vIL-6 
were added. Flag-tagged vIL-6 bound to sgp130 was detected by an anti-flag antibody. C “Sandwich” 
ELISA: MAV bound to vIL-6 (1 µg/ml) could be detected by an anti-myc antibody (last column 
right). vIL-6 bound to gp130Fc (1µg/ml) could not be detected by MAV any more (first column left).  
 
3.2.4.5 Neutralising properties of MAV 
Baf/3-gp130 cells can be used to measure the biological activity of vIL-6 [72]. 500 
ng/ml of recombinant vIL-6 was sufficient to induce cell proliferation (Fig. 3.1.11). The 
absence of vIL-6 or blocking its activity led to no cell proliferation and cell death. To 
analyse whether MAV neutralises the activity of vIL-6, Baf/3-gp130 and Baf/3-gp130, IL-
6R cells were stimulated with 500 ng/ml vIL-6 in the presence of increasing amounts of 
MAV. As a control, the same cells were grown in the presence of Hyper-IL-6 and huIL-6, 
respectively. MAV did not have an inhibitory effect on the cell proliferation induced by 
these cytokines. However, adding of MAV to cells stimulated with vIL-6 did not inhibit cell 
proliferation either (Fig. 3.2.20).  
 
M. Kovaleva „Recombinant antibodies against viral interleukin-6“                                                             Results 
 55 
Baf/3-gp130, IL-6R
100 1000 10000
0
10000
20000 huIL-6+MAV
vIL-6+MAV
concentration, ng/ml
Baf/3-gp130
100 1000 10000
0
10000
20000
30000
40000 HIL-6+MAV
vIL-6+MAV
concentration, ng/ml
Ø
MAV
MAV concentration, ng/ml MAV concentration, ng/ml
Ø
MAV
 
Fig. 3.2.20 Cytokine-induced cell proliferation in the presence of MAV: Baf/3-gp130 cells were stimulated 
with Hyper-IL-6 (1ng/ml) and vIL-6 (500ng/ml). Baf/3-gp130, IL-6R cells were stimulated with huIL-6 
(1ng/ml) and vIL-6 (500ng/ml). Simultaneously, cells were treated with increasing amounts of MAV. 
Proliferation of cells was assessed by measuring of [3H]thymidine incorporation into DNA. 
 
Another possibility to test whether MAV neutralises the vIL-6 effect is to analyse the 
signal transduction induced by vIL-6 in the presence of MAV. vIL-6 binds to the gp130 
receptor, which becomes activated via phosphorylation and induces the JAK/STAT 
signalling pathway [72]. Active STAT3 can be detected in the cell lysate with an anti-
phospho-STAT3 antibody. Inactive vIL-6 would not be able to induce signaling and STAT3 
phosphorylation. HepG2 (human hepatocarcinoma cell line) cells were stimulated with 150 
ng/ml vIL-6 alone or in the presence of increasing concentrations of MAV. Subsequently, 
Western blot analysis of the cell lysates was done using an anti-phospho-STAT3 antibody. In 
fact, MAV reduced STAT3 phosphorylation in a dose-dependent manner indicating some 
neutralising potential of the MAV protein (Fig.3.2.21). 
P-STAT3
STAT3
vIL-6 -- +                   +                +         +
MAV -- -- 150ng/ml      1.5µg/ml       15µg/ml
 
Fig. 3.2.21 vIL-6-induced STAT3 activation in human hepatoma cells: HepG2 cells were 
stimulated with 150ng/ml vIL-6 in the absence or presence of MAV for 10min. Cells were lysed and 
proteins were separated by SDS-PAGE and blotted onto PVDF membrane. Phosphorylated STAT3 
protein was detected by Western blotting using a phospho-STAT3 antibody. 
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3.2.4.6 Binding kinetics of MAV to recombinant vIL-6 
The kinetics of MAV binding to vIL-6 immobilised on a solid phase was analysed by 
surface plasmon resonance (SPR) [150, 151]. SPR arises when light is reflected under 
specific conditions from a conducting film at the interface between two media of a different 
refractive index. The media are the sample (immobilised vIL-6) and the glass of the sensor 
chip, and the conducting film is a thin layer of gold on the chip surface. The resonance is the 
result of energy transformation from photons into surface plasmons and causes a reduction in 
the intensity of reflected light at a specific angle of reflection (Fig. 3.2.22). This angle varies  
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Fig. 3.2.22 Principle of plasmon resonance: Schematic illustration of the chip for SPR. Binding of 
molecules to the sensor surface reduces the intensity of reflected light at a specific angle of reflection. 
 
with the refractive index close to the surface on the opposite side of the film from the 
reflected light. When molecules in the sample bind to the sensor surface, the concentration 
and therefore the refractive index at the surface changes and an SPR response is detected. 
vIL-6 was immobilised to a biosensor surface consisting of an approximately 200 nm thick 
layer of carboxymethyl dextran (CMD). Dextran, a polymer of glucose residues with a low 
degree of branching, has a low polydispersity and an approximate molecular weight of 500 
kDa. When it is carboxymethylated it has one carboxyl group (pKa=3.5) per two glucose 
residues. Hence, the CMD surface is negatively charged in buffers with a pH below 5.0. If 
the buffer pH is lower than the isoelectric point (pI) of a protein, the protein will exhibit a net 
positive charge and will be bound to the matrix by electrostatic interaction. The 
immobilisation of vIL-6 to CMD was achieved by coupling the protein’s primary amino 
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Fig. 3.2.23 Plasmon resonance: Chemistry for immobilisation of biomolecules to CMD via 
EDC/NHS chemistry. CMD- carboxymethyl dextran; EDC- 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide; NHS- N-hydroxysuccinimide; ligand- in this case vIL-6. 
 
groups (N-terminal and lysine residues) to the carboxylate groups of CMD via EDC/NHS 
chemistry (Fig. 3.2.23 and 3.2.24). Free active carboxy groups were eliminated by 
ethanolamine. 
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Fig. 3.2.24 Immobilisation of vIL-6 to CMD using EDC/NHS:  
1- Experiment time: 3.0: activation with EDC/NHS (3x200µl) 
2- Experiment time: 13.9: PBS-T wash (3x200µl) 
3- Experiment time: 18.3: change to 10mm acetate pH=5.0 (3x200µl) 
4- Experiment time: 22.2: added 40µg vIL-6 in 10mm acetate pH=5.0 
5- Experiment time: 31.3: PBS-T wash (3x200µl) 
6- Experiment time: 42.2: block with 1M ethanolamine pH=8.5 (3x200µl) 
7- Experiment time: 47.0: PBS-T wash (3x200µl) 
CMD- carboxymethyl dextran; EDC- 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; 
NHS- N-hydroxysuccinimide 
 
2
 
Fig. 3.2.25 Association-dissociation curve of MAV binding to immobilised vIL-6: 
1- Experiment time: 18: adding of MAV (association curve) 
2- Experiment time: 23.5: PBS-T wash (dissociation curve) 
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CMD immobilised with vIL-6 was then used to measure the binding kinetics of MAV 
to vIL-6. Binding of MAV led to an increasing protein mass on the biosensor surface and to 
changes of the refractive index. This was detected and expressed as association curves. By 
replacing MAV with buffer, dissociation of MAV could be detected (Fig. 3.2.25). 
The theoretical model of interaction of a single molecule of ligand (vIL-6) with one 
molecule of ligates (MAV) can be described as: 
                                           
kass     
[vIL-6] + [MAV] ↔ [vIL-6/MAV] 
                                          kdiss 
 
The rate of complex formation is described by the second order association rate 
constant kass which has units of M-1s-1. The rate of complex dissociation is described by kdiss, 
the first order dissociation constant which has units of s-1.  
The amount of [vIL-6/MAV] complex formed in time t is given by: 
[vIL-6/MAV]t = [vIL-6/MAV]eq[1-exp(-Kont)] 
In this equation [vIL-6/MAV]eq is the concentration of complex at equilibrium. Kon is 
the pseudo-first order rate for the interaction where: 
Kon = kass [MAV] + kdiss 
Hence, Kon varies with ligand concentration. 
The instrument response R (measured in arc seconds) is proportional to the mass of 
bound MAV, resulting in: 
Rt = (Req – R0)[1-exp(-Kont)] + R0, 
where Rt is the response at time t, R0 is the initial response, and Req the maximal response. 
Multiple determinations of Kon were obtained by repeating associations at various 
concentrations of MAV (Fig. 3.2.26). Hence, a plot of multiple Kon values, derived from a 
full interaction experiment, allowed determining kass (gradient) and kdiss (intercept) (Fig. 
3.2.26 B), which was 14500.5 M-1s-1 and 0.005012 s-1, respectively. In this way, the affinity 
of MAV to vIL-6 was defined as dissociation equilibrium constant KD = kdiss/ kass =340nM. 
The affinity of MAV to vIL-6 was also determined by ELISA. MAV was added to 
immobilised vIL-6 in a range from 0 to 10 µg/ml. Bound MAV was detected by an anti-myc 
antibody and an anti-mouse-AP as secondary antibody. The extinction curve of the AP 
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Fig. 3.2.26 Kinetics of binding of MAV to vIL-6 bound to a solid phase: A Association of 
MAV to immobilised vIL-6 led to the increase of the resonance angle α as a function of time. The 
association phase was recorded for different nanomolar MAV concentrations as indicated. B 
Calculation of the data from A allows the determination of the dissociation rate constant kdiss from 
the ordinate intercept and the association rate constant kass from the slope of the graph.     
 
reaction with substrate pNPP can be seen in figure 3.2.27. In the Scatchard analysis [152] the 
dissociation equilibrium constant (KD) is defined as the ligate concentration at which half the 
number of binding sites of the ligand (Bmax/2) is bound. The MAV concentration at which 
Bmax/2 of vIL-6 is at extinction 0.8, can be graphically determined as 0.5 µg/ml (Fig. 3.2.27). 
It was calculated to 17 nM (MrMAV = 30118Da). The 20-fold difference between the KD 
measured by plasmon resonance and the one determined by ELISA could be explained by 
the different 
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Fig. 3.2.27 Scatchard analysis: vIL-6 (1 µg/ml) was coated on the plate and ELISA with different 
concentrations of MAV was done. Bmax/2 = 0.8 that correlated with C(MAV) ~ 0.5 µg/ml = 17 nM. 
KD(MAV) =  17nM. 
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methods and experimental conditions used. Similar differences were consistently observed 
for other proteins, too, e.g. for huIL-6 and the sIL-6R [153].  
  
3.2.5 Model system for the intracellular retention of vIL-6 
Secreted vIL-6 exhibits its effect extracellularly via binding to the receptor 
homodimer of gp130 leading to signal induction [72]. Such an effect of vIL-6 can be 
neutralised by a suppression of its secretion. This can be realised by transfection of cells 
expressing vIL-6 with the cDNA coding for an antibody carrying the endoplasmic retention 
sequence KDEL (lys-asp-glu-leu) at the COOH-terminus. Proteins carrying the KDEL are 
recognised by the KDEL receptor in early Golgi compartments and are returned to the 
endoplasmic reticulum [154, 155]. To test for the intercellular retention of vIL-6, the MAV 
antibody fragment was fused with a COOH-terminal KDEL sequence, and COS-7 cells were 
used as a cell model system for intracellular retention of vIL-6 by ER anchored MAV-
KDEL.  
 
3.2.5.1 Cloning and expression of the recombinant antibody 
carrying the retention sequence KDEL 
In eukaryotic cells, proteins destined for export from the cell are usually synthesised 
with an amino-terminal signal peptide. To clone a construct for eukaryotic expression of 
MAV-KDEL, the signal peptide of human IL-6 was added to the N-terminus and KDEL to 
the C-terminus of MAV (Fig. 3.2.28). The signal peptide was amplified by PCR using the 
primers MK104 and MK704. The MAV sequence was amplified from pIT1-MAV 
employing the forward primer MK304 and the reverse primer MK404 that included 12 
nucleotides encoding the KDEL. The complete sequence of MAV with its signal peptide was 
obtained employing Splicing by Overlap Extension (SOE)-PCR [156-159] using the terminal 
primers MK104 and MK404 (Fig. 3.2.28 A and description in 2.2.2). Subsequently, the SP-
MAV was cut with PmeI (which generates blunt ends) and cloned into the cloning vector 
pESL (Gibco; modified in our lab) opened by EcoRV (which also generates blunt ends). The 
gene of interest was then moved from the cloning vector into the expression vector by the 
LR-clonase reaction. In the LR-clonase reaction, DNA segments are transferred between a 
cloning vector and an expression vector using phage lambda-based site specific 
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recombination (Gateway cloning technology, Gibco) [160, 161]. As expression vector the 
p409B plasmid was used (Fig. 3.2.28 B).  
MK104 5‘- CA CGT TTA AAC GCC ACC ATG AAC TCC TTC TCC ACA -3‘
MK704 5‘- CAA CAG CTG CAC CTC GGC CAT CAC GTG TAC TGG GGC AGG GAA GGC -3‘
MK304 5‘- ATG GCC GAG GTG CAG CTG -3‘
MK404 5‘- GT GGT TTA AAC CTA GAG TTC GTC TTT CCG CGG ATT CAG ATC CTC TTC TGA -3‘
MK104 MK304
MK704
KDEL*
MK404
SOE-PCR
SP MAV
MK104
KDEL*
MK404
SP MAV
A
B
 
Fig. 3.2.28 MAV-KDEL-expression construct: MAV and the signal peptide of huIL-6 were 
amplified by SOE-PCR, cloned into an entry vector and recloned into the expression destination vector 
p409B via LR-clonase reaction (Gateway cloning technology). A Primer sequences and schematic 
illustration of SP-MAV amplification, SP- signal peptide of huIL-6, MAV- recombinant antibody 
fragment against vIL-6, KDEL- retention sequence, *- stop-codon, SOE-PCR- splicing by overlap 
extension polymerase chain reaction; B Vector map of p409B-MAV-KDEL, SV40- SV40 promoter; 
AttB1/2- DNA recombinant sequences; huIL-6-SP- signal peptide of human IL-6; KDEL- KDEL 
sequence. 
 
p409B-MAV-KDEL was transfected into COS-7 cells and MAV-KDEL expression was 
analysed by Western blotting of the cell lysate and the cell medium (supernatant). The anti-
myc 9E10 antibody was used for MAV detection. As expected, the MAV-KDEL was 
detected in the cell lysate and was not detectable in the cell supernatant (Fig. 3.2.29). The 
expression of MAV and its localisation within the cell was additionally monitored by 
immunostaining of transfected COS-7 cells. MAV was stained by an anti-myc antibody 
followed by the anti-mouse Alexa Fluor 594 antibody, which can be detected by red 
fluorescence. As expected, the red fluorescence corresponding to MAV-KDEL was seen in 
the region of the endoplasmic reticulum and no plasmamembrane staining was detected (Fig. 
3.2.30 c-d).  
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Fig. 3.2.29 Western blot analysis of the MAV-KDEL expression in COS-7 cells: Supernatants of 
the cells transfected with p409B-MAV-KDEL and cell lysates were prepared on the second day after 
transfection. MAV-KDEL was detected by Western blotting using an anti-myc antibody. 
 
 
a) b)
c) d)
 
Fig. 3.2.30 Immunofluorescence of COS-7 cells transfected with p409B-MAV-KDEL: Cells on the 
3rd day after transfection were stained with an anti-myc antibody (1:100) and the Alexa Fluor 594 anti-
mouse antibody (1:1500) (b-d). Control staining (a) was prepared without an anti-myc antibody.  
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3.2.5.2 Cloning and expression of vIL-6 fused to GFP 
To show if retention of vIL-6 occurs in the ER due to its binding to MAV-KDEL and 
if both proteins co-localise in transfected COS-7 cells, vIL-6 was fused to the Green 
Fluorescent Protein (GFP). The green fluorescence of GFP can be observed microscopically 
after excitation at 488 nm using a fluoresceinisothiocyanate (FITC)-filter. The expression 
level of the protein can be estimated by the intensity of the green light. Additionally, the 
intracellular localisation of the protein can nicely be visualised. Plasmid pcDNA3.1-GFP 
was opened by NheI and XhoI. vIL-6 amplified with the primers MK504 and MK604 was 
cut with the same restriction endonucleases and inserted into the vector (Fig.3.2.31). The 
expression of this  
 
MK504 5‘- CA CTA GCT AGC GCC ACC ATG TGC TGG TTC AAG TTG -3‘
MK604 5‘- CCG CTC GAG CTT ATC GTG GAC GTC AGG -3‘
 
Fig. 3.2.31 Primer sequences for vIL-6 amplification and plasmid map of the vIL-6-GFP-
expression vector: vIL-6 was amplified and cloned into the vector pcDNA3.1-GFP via NheI and XhoI. 
Amp- ampicillin resistance gene; Cmv- cytomegalovirus promoter; GFP- green fluorescent protein. 
 
construct was checked via transient transfection of COS-7 cells. The green fluorescence of 
the cells expressing vIL-6-GFP was observed microscopically (Fig. 3.2.32). Strong 
fluorescence of the ER suggested a high expression level of vIL-6-GFP. The secretion of 
vIL-6-GFP was identified in Golgi vesicles seen as green dots (Fig. 3.2.32, white arrows) 
and observed as green fluorescence in the region of the plasmamembrane. Using an anti-vIL-
6 serum for Western blot analysis, vIL-6-GFP was detected in the supernatant as well as in 
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the cell lysate of transfected COS-7 cells (Fig.3.2.33). The double band corresponding to 
vIL-6-GFP in the supernatant most likely reflects diffetentially glycolysated forms of vIL-6-
GFP. 
 
a) b)
 
Fig. 3.2.32 Fluorescence microscopy of untransfected (a) and with pcDNA3.1-vIL-6-GFP(b) 
transfected COS-7 cells.   
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Fig. 3.2.33 Western blot analysis of vIL-6-GFP expression in COS-7 cells: Supernatants of cells 
transfected with pcDNA3.1-vIL-6-GFP and cell lysates were prepared on the second day after 
transfection. vIL-6-GFP was detected in the Western blot using an anti-vIL-6 serum [69]. 
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3.2.5.3 Retention of vIL-6 in the ER due to binding to MAV-
KDEL 
As demonstrated, vIL-6-GFP is secreted from transfected COS-7 cells, whereas 
MAV-KDEL is retained in the endoplasmic reticulum. The co-transfection of vIL-6-GFP 
and MAV-KDEL into COS-7 cells should result in intracellular binding of vIL-6-GFP to 
MAV-KDEL and in the retention of MAV-KDEL/vIL-6-GFP in the endoplasmic reticulum. 
This was demonstrated by Western blot analysis of the lysates and supernatants of the co-
transfected COS-7 cells. vIL-6-GFP was detected in the cell supernatant by an anti-vIL-6 
serum when the cDNA was transfected into the cells alone, but was not found to be secreted 
from the cells when co-transfected with MAV-KDEL cDNA (Fig.3.2.34). Interestingly, the 
expression of vIL-6 was lower after co-transfection with MAV-KDEL. By  
vIL-6-
GFP
vIL-6-
GFPGFP GFP
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GFP+
MAV-
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Fig. 3.2.34 Co-transfection of MAV-KDEL and vIL-6-GFP cDNAs into COS-7 cells resulting in 
intercellular retention of vIL-6: COS-7 cells were transfected with pcDNA3.1-vIL-6-GFP alone or 
co-transfected together with p409B-MAV-KDEL. Supernatants and lysates of the cells were prepared 
on the second day after transfection, separated by SDS-PAGE and blotted onto a PVDF membrane. 
vIL-6-GFP was detected by Western blotting using an anti-vIL-6 serum. 
 
fluorescence microscopy, intracellular binding and co-localisation of vIL-6 and MAV-KDEL 
could be observed as yellow staining caused by the fusion of green (vIL-6-GFP) and red 
(MAV-KDEL-Alexa Fluor 594) fluorescence. Fig. 3.2.35 shows a cell with stronger 
expression of MAV-KDEL (left) and a cell with stronger expression of vIL-6-GFP (right). 
Consequently, we observed in the overlap picture more red fluorescence of the cell over-
expressing MAV-KDEL, and more green fluorescence of the cell over-expressing vIL-6-
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GFP. Clearly, yellow staining caused by co-localisation of MAV-KDEL and vIL-6-GFP was 
detected. 
 Taken together, vIL-6 secretion seems to be successfully suppressed due to binding 
to MAV-KDEL and retention of the vIL-6/MAV-KDEL complex in the ER. This experiment 
at cell-line level gives good reason to hope that future in vivo experiments with a mouse 
model will also result in inhibition of vIL-6 secretion. 
 
a)
c)
b)
 
Fig. 3.2.35 Immunofluorescence of COS-7 cells co-transfected with p409B-MAV-KDEL and 
pcDNA3.1-vIL-6-GFP: Cells on the 3rd day after transfection were fixed and stained with an anti-
myc antibody (1:100) and the Alexa Fluor 594 anti-mouse antibody (1:1500). Co-transfected cells 
were analysed microscopically. The expression of vIL-6-GFP is shown in green using a FITS-filter (a). 
The expressed MAV-KDEL was immunostained with the antibody fluorescing in red (b). The co-
localisation of vIL-6-GFP and MAV-KDEL is seen in yellow (c). A 543-fold magnification was used 
to photograph the cells.  
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4 Discussion 
In this study antibodies against viral interleukin-6 (vIL-6) were produced for 
neutralisation of the biological effect of vIL-6. Encoded by Human Hepesvirus-8 (HHV-8), 
viral IL-6 is believed to play an important role in the pathogenesis of Kaposi’s sarcoma 
associated diseases. An antibody screened from a phage display human library is a promising 
candidate for the therapy of these diseases. To eliminate cells infected with HHV-8 different 
strategies were developed.  
 
4.1 Expression, purification and biological activity of viral 
interleukin-6 
In the first part of this study the production of recombinant vIL-6 was described. The 
biologically active pure protein was needed for the screening and selection of recombinant 
antibody fragments. Using a bacterial system for the expression of vIL-6 was not successful.  
Although it ensured a rapid production of vIL-6 in large amounts, the expressed protein was 
biologically inactive and was not able to induce proliferation of Baf/3-gp130 cells (Fig. 
3.1.5). Changing to a eukaryotic expression system turned out to be worthwhile.  vIL-6 
isolated from the supernatant of EBNA-293-cells stably transfected with vIL-6 cDNA 
induced Baf/-gp130 cell proliferation at a concentration of 100 ng/ml. EBNA-293 cells were 
transfected with two constructs encoding vIL-6: vIL-6 with an N-terminal his-tag and vIL-6 
with an N-terminal flag-tag and a C-terminal his-tag. The his-tag was critical for the protein 
purification by Ni-NTA agarose. The advantage of the secreted expression in mammalian 
cells over bacterial expression of vIL-6 in insoluble form is the native fold of the protein. 
The results of the CD-spectra shown in Fig. 3.1.10 supported the alpha-helical fold of 
EBNA-293 secreted vIL-6 proteins. The bacterial expressed vIL-6 was not completely 
folded, which could explain the lack of its biological activity and incapability to induce Baf/-
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gp130 cell proliferation. The incomplete folding of recombinant proteins produced as 
insoluble inclusion bodies in a bacterial expression system is not an unusual observation 
[162]. Denaturation in a strong chaotropic agent followed by refolding in a redoxsystem-
containing buffer does not always lead to the correct formation of the disulfide bridges. 
Moreover, bacterial proteins are usually unglycosylated, but vIL-6 N89-glycosylation could 
be important for the biological activity of the cytokine and for stimulating vIL-6-dependent 
cell proliferation [74].  
About 7 mg of flag-vIL-6-his was expressed and purified from EBNA-293-
supernatant and used for the production and characterisation of recombinant antibodies. His-
vIL-6 from EBNA-293 cells was expressed in small amounts to be used as a control antigen 
to rule out any specificity of the produced antibodies for the flag-tag. 
 
4.2 Phage display: human antibody library 
For the production of recombinant antibodies against vIL-6, which was subject of the 
second part of the study, the phage display technology was chosen.  
The phage display of antibody fragments scFv [163] has its origins in experiments 
demonstrating that small proteins and peptides could be displayed on the surface of 
filamentous bacteriophage [143, 144]. Since the generation of the first human antibodies by 
phage display [5], the technology has developed to the point where large scFv repertoires 
have been created that yield antibodies with sub-nanomolar affinities [164, 165]. This is 
comparable with the best antibodies obtained using hybridoma technology. Phage display 
repertoires can also be used to isolate antibodies not easily obtained by hybridoma 
technology, such as those specific for toxic proteins and human anti-self antibodies [166, 
167]. The using of monoclonal antibodies in the clinic has, until recently, been limited 
because they were originally derived by hybridoma technology and so were recognised by 
the human immune system as foreign. Attempts to humanise murine monoclonal antibodies 
and the development of chimeric antibodies has resulted in a number of these antibodies 
progressing through clinical trials [168]. However, both humanised and chimeric antibodies 
are still a combination of human and mouse sequences and the presence of any mouse 
protein is a disadvantage that could potentially result in a human anti-mouse antibody 
(HAMA) reaction. Therefore, phage display technology provides a means by which high 
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affinity, fully human monoclonal antibodies can be rapidly isolated and also provides a 
starting point from which a selected antibody can, if necessary, be affinity matured for 
improved neutralisation potency or binding kinetics. The use of naturally rearranged 
germline fragments in the construction of the library ensures that these fully human scFv 
fragments are unlikely to be immunogenic making them ideal therapeutic agents.  
 
4.3 Properties of the selected scFv against vIL-6 
As described, only one scFv antibody fragment specific for vIL-6 (MAV) was 
selected from the Tomlinson libraries A and B (Tomlinson, MRC, University of Cambridge, 
UK). The high specificity of MAV for vIL-6 was observed by ELISA. Because the 
recombinant flag-vIL-6-his was used for scFv screening and selection, it was necessary to 
proof that MAV is not specific for the flag- or his-tag. The binding of MAV to his-vIL-6 
without flag-tag suggested that MAV did not recognise the flag-sequence. Besides, MAV did 
not react with his-tagged OSM, underlining that MAV is not specific for the his-tag either. 
Importantly, MAV was not cross-reactive with other antigens and did not bind to human IL-
6. 
The fact that MAV recognised vIL-6 in both the ELISA and the Western blot makes 
the antibody a suitable immunological reagent to detect vIL-6. However, an antibody which 
might be used for therapy has to recognise the antigen in solution. That MAV indeed is 
capable of doing so was demonstrated when vIL-6 secreted into the supernatant of 
transfected COS-7 cells bound to and was precipitated by MAV. The fact that MAV 
precipitated unglycosylated as well as glycosylated vIL-6 (Fig. 3.2.16) demonstrated that 
there was no reactivity of MAV for carbohydrate-residues.  
The dissociation constant of MAV to vIL-6 was determined by plasmon resonance as 
340 nM, which is about 10-fold lower than the dissociation constant of sgp130 to vIL-6, 
determined by the same method (2.5 µM) [68]. Still, for an antibody screened from the 
Tomlinson human antibody library, this is surprisingly low [167]. In previous studies it was 
shown that the affinity of an antibody to an antigen that is immobilised on a solid phase is 
10-100-fold lower than the one measured in solution (Tab. 4.1) [32, 119, 153, 169, 170, 
171]. The difference might be a result of the different methods employed. Therefore, the 
binding kinetics of MAV to vIL-6 was measured and calculated by Scatchard analysis [152]. 
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The calculated KD was 17 nM, which is a reasonable value for an antibody obtained by 
phage display [167]. 
The MAV binding epitope of vIL-6 was identified on the D-helix of site III. As it is 
known, site III of vIL-6 is the binding site for the gp130 receptor [68]. Using the “sandwich” 
ELISA it was shown that vIL-6 bound to sgp130Fc could not bind to MAV any more. 
Tab. 4.1. Comparison of the affinity of a ligate to its ligand that is either immobilised on a solid phase 
or in solution 
Binding assay on the solid phase 
immobilised ligand ligate Kd, nM Ref. 
IL-6 sIL-6R 34 [153] 
sgp130Fc  HIL-6 4.2 [32] 
vIL-6 MAV 340 this study 
Binding assay in solution 
ligand ligate Kd, nM Ref. 
IL-6 sIL-6R 0.5 [153] 
sgp130Fc HIL-6 0.06 [171] 
vIL-6 MAV 17 this study 
 
Possibly, site III of vIL-6 was first occupied with sgp130Fc leaving no free binding 
epitope for MAV. It would be interesting to find out whether vice versa sgp130Fc can bind 
to vIL-6 which has already bound to MAV. Moreover, it remains to be clarified what 
happens when MAV and sgp130Fc directly compete for vIL-6 binding when added together.  
If MAV and gp130 interact with the same vIL-6 epitope, binding of MAV to vIL-6 in 
vivo should abrogate the signaling occurring upon vIL-6 binding to gp130 [68]. Stimulation 
of HepG2 cells with vIL-6 results in phosphorylation of STAT3 [77]. Adding of MAV led to 
reduced signaling and decreased STAT3 phosphorylation in a dose-dependent manner (Fig. 
3.2.21). On the other hand, treatment of the cells with 15µg/ml of MAV did not completely 
eliminate the phosphorylation of STAT3.  Moreover, MAV was not able to inhibit Baf/3-
gp130 cell proliferation induced by vIL-6. A possible reason for this could be that MAV 
became instable during the 72h proliferation assay. In contrast, the stimulation of HepG2 
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cells in the presence of MAV lasted only 10 min and resulted in a decrease of vIL-6-induced 
STAT3 phosphorylation. Taken together, this suggests that MAV exhibits some neutralising 
activity which, however, is not sufficient to fully abrogate the vIL-6 effect. Strategies to 
increase MAV’s neutralising properties, for example, by fusion with a cellular toxin, will be 
the objective of future experiments.  
 
4.4 Elimination of vIL-6 secretion 
The synthesis of all proteins occurs at the ribosomes, where they are assigned to two 
different pathways: proteins with a signal peptide for the endoplasmic reticulum (ER) take 
the secretory pathway, while proteins without such a signal peptide take the cytoplasmic 
pathway. Secreted proteins are transported in vesicles from the ER to the Golgi-apparatus 
and then to the plasmamembrane. The proteins which are destined for the ER, are returned to 
the ER due to their COOH-terminal retention signal (Fig. 4.1).  
 
- MAV-KDEL
- viral IL-6
 
Fig. 4.1. Protein synthesis and schematic illustration of vIL-6/MAV-KDEL retention.  All proteins 
are synthesised at the ribosomes of the endoplasmic reticulum (ER) and take the cytoplasmic or secretory 
pathway, dependent on their function. MAV containing the endoplasmic retention sequence returns to the 
ER and will not be secreted. vIL-6 bound to MAV-KDEL will not be secreted, either.  
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The synthetic fusion of a retention sequence to a protein which originally does not 
have such a sequence, leads to inhibition of its secretion and to its localisation in the ER. For 
example, recombinant human IL-6 carrying a retention signal accumulated intracellularly 
and therefore was able to inhibit the surface expression of IL-6R [120]. 
In this study, the construction of an anti-vIL-6 antibody (MAV) carrying the retention 
signal (KDEL) was described.  Antibody retention in the ER was demonstrated by 
transfection of COS-7 cells with a plasmid encoding MAV-KDEL. Co-transfection with vIL-
6 resulted in intracellular binding of vIL-6 to the antibody and in retention of vIL-6/MAV-
KDEL in the ER.  Using this cell model system, the secretion of vIL-6 was completely 
eliminated. Moreover, the expression of vIL-6 was lower after the co-transfection with 
MAV-KDEL (Fig. 3.2.35).   
Very recently a paper about an intracellular signaling mechanism of vIL-6 was 
published [172]. It was speculated that only a small proportion of expressed vIL-6 is secreted 
and that intracellular signal activation via IL-6 is predominant. If this is the case, the MAV-
KDEL antibody might have a beneficial effect by specifically blocking vIL-6 secretion and 
by neutralising vIL-6-induced signaling.  In this study, the lack of vIL-6 secretion from cells 
co-transfected with MAV-KDEL cDNA was demonstrated. Additionally, it was shown that 
MAV is able to inhibit the signaling induced by stimulation of HepG2 cells with vIL-6 (Fig. 
3.2.21). An important objective of future experiments will be the analysis of the neutralising 
property of the fusion antibody MAV-KDEL.  
 
4.5 HHV-8 associated diseases and potential therapeutic 
application of anti-vIL-6 antibodies 
Human herpesvirus 8 (HHV-8), also called Kaposis’s sarcoma associated 
herpesvirus, interferes with the body’s immune response and causes Kaposi’s sarcoma (KS). 
Kaposis’s sarcoma is a cancer of blood vessel cells that often occurs in subepidermal tissues 
or the mucous membrane. Kaposi’s sarcoma is one of the most common malignancies 
occurring among AIDS patients [60, 173]. HHV-8 encodes the cytokine vIL-6, which does 
not only inhibit immune function, but also causes cancerous cells to grow. vIL-6 protects 
virus-infected cells from undergoing growth arrest and apoptosis or cell death, which is one 
strategy the immune system applies to limit viral infection. vIL-6 inhibits the signaling of the 
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antiviral factor interferon which prevents virus-infected cells from growing [85]. In addition, 
in some cells, vIL-6 does not only stop the suppression of tumors, but also causes healthy 
cells that are not infected with HHV-8 to proliferate abnormally [174]. Therefore, vIL-6 is a 
promising target for novel therapies directed against HHV-8-associated tumors.  
Although vIL-6 was initially isolated from Kaposi’s sarcoma lesions, it was also 
found to be associated with lymphoproliferative diseases [175], such as primary effusion 
lymphoma (PEL) and multicentric Castleman’s disease (MCD). Castleman’s disease is a 
non-malignant atypical lymphoproliferative disorder, characterised by lymphadenopathy 
with angiofollicular hyperplasia and plasma cell infiltration. Virtually all HIV-positive 
patients with MCD and nearly 50% of HIV-negative patents are infected with HHV-8 [173, 
176]. Furthermore, some patients have coexistent Kapisi’s sarcoma (18-20%) [177]. Primary 
effusion lymphoma is a malignant effusion in the absence of a contiguous solid tumor mass 
that develops in the pleural, pericardial, or peritoneal cavity. Viral IL-6 is believed to play an 
important role in the pathogenesis of PEL and MCD, acting as an autoctine or paracrine 
factor in the lymphoproliferative processes common to both [178]. Variations in the level of 
vIL-6 expressions have been observed in Kaposi’s sarcoma (~40 copies/cell), PEL (~648 
copies/cell), and MCD (~1800 copies/cell), which may be due to tissue and cell-specific 
environment [178].  
HHV-8 vIL-6 was found to be transcribed in the bone marrow dendritic cells of 
multiple myeloma patients [54]. Multiple myeloma is a fatal cancer characterised by the 
accumulation of malignant plasma cells in the bone marrow. The finding that viral IL-6, like 
human IL-6 [179, 180], induced DNA synthesis of human multiple myeloma cell lines in 
vitro [76], suggests a potential role of HHV-8 in tumor cell proliferation and survival.  
HHV-8-associated tumors are highly aggressive and refractory to therapy. There are 
several approaches to treatment: surgical excisions, laser therapy (argon-laser, CO2-laser), 
photodynamic therapy, or systematic treatment with chemotherapy agents. AIDS-associated 
Kaposi’s sarcoma can be successfully treated by Highly Active Anti-retrovital Therapy 
(HAART), although some HIV-infected patients suffer from herpesvirus-associated immune 
restoration disease after the beginning of HAART [181]. The study using protease inhibitors 
for KS treatment shows the improvement of the residual immune function of the patient and 
can lead to the elimination of KS [182]. Among other approaches for treatment, one can 
modulate the cytokines that cause KS to grow. Unlike other cancers, KS cells cannot grow 
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on their own. The inhibition of the virus’s tat protein is essential to inhibit the growth of 
Kaposi’s sarcoma cells. The neutralisation of vIL-6, the infectious agent of HHV-8 
associated tumors, can be helpful to combat not only KS but also the other HHV-8-
associated diseases. In this respect, recombinant soluble cytokine receptor gp130 (sgp130) 
has a high therapeutic potential. Viral IL-6 affects cells expressing gp130 on their surface. 
Recombinant sgp130 blocks the anti-apoptotic affect of vIL-6 mediated via membranebound 
gp130. On the other hand, sgp130 is an inhibitor of human IL-6 responses dependent on sIL-
6R and therefore is a therapeutic tool to specifically block disease states in which sIL-6 
transsignaling responses exist [32]. A highly specific inhibitor of vIL-6 can be a monoclonal 
antibody against the viral cytokine. 
Phage display antibody technology opens a new spectrum of application of antibodies 
for tumor therapy. The ability to generate scFvs with novel binding capacities in a faster and 
easier way than monoclonal antibodies produced by hybridoma technology, coupled with the 
scFvs’ lower immunogenicity given the lack of the Fc domain, makes them promising 
candidates. The first fully human therapeutic recombinant antibody isolated from a phage 
display library was for the treatment of rheumatoid arthritis and ocular scarring and is 
currently tested in phase II clinical trials [183]. In 1999 about 150 different clinical trials 
were under way employing recombinant antibodies, mostly for the treatment of cancer. 
Keeping in mind the delay between research and even first clinical trials and the approval as 
a drug, it can be expected that recombinant antibody based therapies will be a widespread 
and acknowledged tool in the hands of physicians by the year 2010. 
We have selected the first recombinant antibody against vIL-6, which can be a 
promising candidate for the therapy of HHV-8-associated diseases. As described in this 
work, this antibody (MAV) specifically recognises and binds to native vIL-6. In vivo, MAV 
reduces the effect of viral IL-6 by inhibition of vIL-6 induced signaling.  
Alternatively, a tumor-killing effect of MAV can be obtained from elimination of 
those cells affected by vIL-6. Along with other strategies the design of an antibody carrying 
a cytotoxic agent, for example Pseudomonas exotoxin 38 (PE38), will be subject to future 
experiments. PE is one of the pathogenic proteins secreted by Pseudomonas aeruginosa. PE 
is a cellular toxin reaching the cytosol of cells by receptor-mediated endocytosis [121]. A 
variant PE38 which does not have a cell-binding domain, bound to an antibody, could be 
targeted via the antibody-part to the cells produced vIL-6. It was previously reported that the 
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fusion of huIL-6 with Pseudomonas exotoxin was able to lyse IL-6R expressing myeloma 
cells in vitro [184]. The first scFv-immunotoxin anti-Tac-PE38 is currently progressing 
through phase II clinical trials [121]. We expect that a fusion antibody consisting of MAV 
with the cellular Pseudomonas exotoxin 38 can recognise and selectively destroy the cell 
population affected by vIL-6, and therefore could be tested for therapeutic application. 
Another strategy to target cytokine-secreting cells is based on the production of a 
bispecific antibody (diabody) recognising vIL-6 and the CD3 T cell receptor [185, 186]. 
Such a diabody would stimulate T cell mediated killing of cells that secrete vIL-6. Cells 
which do not express the viral cytokine remain unaffected. The elimination of the infected 
cells would be performed by cytotoxic T cells, which are recruited to the target cells by the 
vIL-6 part of the bispecific antibody. It was previously demonstrated that a diabody 
recognising human IL-6 and the CD3 T cell receptor induces specific lysis of HepG2 cells 
stably transfected with huIL-6 [119]. Interestingly, in contrast to cells secreting huIL-6, 
huIL-6 responder cells remained unaffected by the diabody. It should be noted that the anti-
huIL-6 diabody has not reached therapeutic application so far. The anti-CD3 part of this 
diabody (mAb OKT3) is murine and would have to be humanised, or a recombinant human 
scFv with specificity for human CD3 from phage display library has to be selected.   
For targeted gene therapy of the HHV-8-associated diseases, the anti-vIL-6 antibody 
MAV fused to the endoplasmic retention sequence KDEL (MAV-KDEL) might be useful 
[120]. As described, MAV-KDEL partly blocks the secretion of vIL-6 in COS-7 cells, 
thereby eliminating the autocrine and paracrine effects of the viral cytokine. This successful 
experiment on a cell-line level lets us hope that future in vivo experiments with a mouse 
model will also result in inhibition of vIL-6 secretion.  One can also assume that MAV-
KDEL will exhibit vIL-6-neutralising activity in vivo, which would be of particular 
importance if vIL-6 activity occurs intracellularly.  
This study is an example for the production of recombinant proteins with the desired 
properties for in vivo application. We selected the first human anti-vIL-6 antibody, which 
could have a therapeutic future in the treatment of HHV-8-associated diseases. Based on this 
work, a large variety of other fusion proteins can be constructed and will hopefully 
demonstrate the potential of antibody engineering for generating new therapeutic agents. The 
antibody-based therapeutics has become a rising market that illustrates the substantial 
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change in the pharmaceutical development by utilising the body’s own capabilities as a 
source for drug rather than chemical reagents.  
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5 Summary 
The genome of Human herpesvirus 8 (HHV8), also called Kaposis’s sarcoma 
associated herpesvirus, encodes several ORFs for putative oncogenes, which are homologues 
to cellular host genes known to function in cell-cycle regulation, control of apoptosis and 
cytokine signaling. One of these genes encodes viral interleukin-6 (vIL-6) that exhibits 
24,7% homology to human interleukin-6 (huIL-6). vIL-6 mimics a number of huIL-6 
activities, such as stimulating IL-6 dependent B-cell line growth and activating the 
JAK/STAT3 signaling pathway. Whereas human IL-6 first has to bind to IL-6R before it can 
interact with a homodimer of glycoprotein 130 (gp130) for signal activation, viral IL-6 
directly binds to the signal transducer gp130 and thereby is able to induce the proliferation of 
cells that do not express IL-6R. vIL-6 was shown to induce angiogenesis and 
haematopoiesis. The viral cytokine is believed to play an important role in the pathogenesis 
of Kaposi’s sarcoma as well as primary effusion lymphoma, multicentic Castelman’s disease 
and perhaps multiple myeloma. Therefore, vIL-6 is a promising target for novel therapies 
directed against HHV-8-associated diseases.  
In this study a recombinant antibody against vIL-6 was produced, consisting of a 
variable domain of the heavy chain (VH) and a variable domain of the light chain (VL) of 
human IgG connected to each other by a short linker sequence. This kind of antibody is 
termed “single chain variable fragment” (scFv) and, in this case, was screened from a phage 
display human antibody library. vIL-6, but not huIL-6 or other control antigens, was 
demonstrated to be specifically recognised by this antibody (called MAV). MAV binds to 
recombinant vIL-6 immobilised on a solid phase and to the native cytokine in solution. 
However, vIL-6 bound to its receptor gp130 can not be recognised by MAV, because the 
MAV binding epitop of vIL-6 localises on helix D, which is a part of the receptor binding 
site III of vIL-6. MAV was shown to inhibit vIL-6-induced signaling in human hepatoma 
cells but was not able to suppress the proliferation of Baf/3-gp130 cells stimulated with viral 
IL-6.  
Based on the idea to block vIL-6 secretion, a strategy for the neutralisation of vIL-6 
was developed and tested. The recombinant antibody MAV was fused with the endoplasmic 
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retention sequence KDEL (MAV-KDEL) to be retained in the endoplasmic reticulum. As a 
result, cells secreting vIL-6 ceased to secrete the cytokine after transfection with MAV-
KDEL. The intracellular binding of vIL-6 to its antibody carrying the retention signal 
blocked the transport of expressed vIL-6 to the cell membrane and led to the retention of the 
vIL-6/MAV-KDEL complex in the endoplasmic reticulum. 
The successful in vivo experiments with the MAV and MAV-KDEL antibodies for 
vIL-6 neutralisation and elimination of the HHV-8 infected cells make them promising 
candidates for the treatment of HHV-8 associated diseases. The development and modelling 
of new strategies for application of recombinant antibodies against vIL-6 will be the subject 
of future investigations. 
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6 Zusammenfassung 
Das Genom des Humanen Herpesvirus 8 (HHV8), auch Kaposi Sarkom-assoziiertes 
Herpesvirus genannt, kodiert für mehrere mutmaßliche Oncogene, welche Homologe von 
zellulären Genen sind, die für die Regulation des Zell-Zyklus, für die Kontrolle der 
Apoptose sowie der Signalübertragung durch Zytokine von Bedeutung sind. Eines dieser 
Gene kodiert für virales Interleukin-6 (vIL-6), das 24,7 % Homologie zu humanem 
Interleukin-6 (huIL-6) aufweist. Einige Wirkungen des huIL-6 können von vIL-6 imitiert 
werden. Zum Beispiel ist es in der Lage, das Wachstum IL-6-abhängiger B-Zelllinien zu 
stimulieren und die JAK/STAT3 Signaltransduktion zu aktivieren. Während humanes IL-6 
zunächst an den IL-6 Rezeptor (IL-6R) binden muss, bevor es mit einem Homodimer des 
Glykoprotein 130 (gp130) interagieren kann, um die Signaltransduktion zu aktivieren, bindet 
virales IL-6 direkt an gp130. Dadurch kann es auch die Proliferation von Zellen induzieren, 
die keinen IL-6R exprimieren. Es wurde bereits gezeigt, dass vIL-6 Angiogenese und 
Hämatopoese induziert. Vor diesem Hintergrund spielt das virale Zytokin eine wichtige 
Rolle in der Pathogenese des Kaposi Sarkoma, des Primären Effusions Lymphoms, der 
Castleman Krankheit sowie des Multiplen Myeloms.  
In vorliegender Arbeit wurde ein rekombinanter Antikörper gegen vIL-6 generiert, 
der aus einer variablen Domaine der schweren Kette und einer variablen Domaine der 
leichten Kette des humanen IgG besteht, verbunden durch eine kurze Linker-Sequenz. Diese 
Art Antikörper wird „single chain variable fragment“ (scFv) genannt und wurde in dieser 
Arbeit mittels einer humanen Phagen-Oberflächenpräsentations-Bibliothek selektioniert. Es 
wurde gezeigt, dass vIL-6, aber nicht huIL-6 oder andere Kontroll-Antigene, spezifisch von 
diesem Antikörper, der „MAV“ genannt wurde, erkannt wird. MAV bindet sowohl an 
rekombinantes vIL-6, das auf einer festen Phase immobilisiert wurde, als auch an das native 
Zytokin in Lösung. Allerdings wird vIL-6, das an seinen Rezeptor gp130 gebunden ist, nicht 
von MAV erkannt, da das Bindungsepitop von vIL-6 für MAV auf der D-Helix liegt, welche 
einen Teil der Rezeptor-Bindungsstelle III für vIL-6 darstellt. Weiterhin wurde gezeigt, dass 
MAV die durch vIL-6 induzierte Signalaktivierung in menschlichen Hepatomzellen 
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inhibieren kann, aber nicht in der Lage ist, die Vermehrung von Baf/3-gp130-Zellen, die mit 
viralem IL-6 stimuliert wurden, zu verhindern.  
Basierend auf der Idee, die Sekretion von vIL-6 aus infizierten Zellen zu blockieren, 
wurde eine Strategie zur intrazellulären Neutralisierung von vIL-6 entwickelt und getestet. 
Der rekombinante Antikörper MAV wurde mit der endoplasmatischen Retentionssequenz 
KDEL fusioniert (MAV-KDEL), um im Endoplasmatischen Reticulum zurückgehalten zu 
werden. Die Folge war, dass Zellen nach kurzer Zeit aufhörten vIL-6 zu sezernieren, 
nachdem sie mit  MAV-KDEL transfiziert worden waren. Die intrazelluläre Bindung von 
vIL-6 an MAV-KDEL hatte zur Zurückhaltung von vIL-6/MAV-KDEL im 
Endoplasmatischen Reticulum geführt. 
Die erfolgreichen in vivo Experimente mit MAV und MAV-KDEL zur vIL-6 
Neutralisierung und Eliminierung vIL-6 sezernierender Zellen machen die beiden Antikörper 
zu aussichtsreichen Kandidaten für die Behandlung von HHV-8-assoziierten Krankheiten. 
Die Entwicklung neuer Strategien und Modelle zur Anwendung rekombinanter Antikörper 
gegen vIL-6 wird das Thema zukünftiger Arbeiten sein. 
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8 Appendix 
8.1 Abbreviations 
Ab – antibody 
Ag – antigen 
AIDS – aquired immuno deficiency syndrome 
Amp – ampicillin 
AP – alkaline phosphates 
APP – acute phase proteins 
APS – ammonium persulfate 
BSA – bovine serum albumine 
CD – circular dichroism  
CDR - complementarity determining regions 
CLC - cardiotrophin-like cytokine 
CMD - carboxymethyl dextran 
CNTFR - ciliary neurotrophic facto receptor 
CT-1 – cardiotrophin-1 
DEAE - diethylaminoethyl 
DMSO – dimethyl sulfoxide 
dNTP – 2’-desoxyribonucleotide-5’-triphosphate 
EDC - 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
EDTA – ethylendiamintetraacetic acid 
ELISA – enzyme linked immunosorbent assay 
ER – endoplasmic reticulum 
FCS – fetal calf serum 
FITC – fluorescein isothiocyanate 
GFP – green fluorescent protein 
gp – glycoprotein  
Grb2 - growth-factor-receptor-bound protein 
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h - hour 
HAMA - highly active anti-retrovital therapy 
HHV-8 – human herpesvirus-8 
HIL-6 – Hyperinterleukin-6 
his – histidin 
huIL-6 – human interleukin-6 
IFNγ – interferon γ 
Ig – immunoglobulin 
IL - interleukin 
IPTG – isopropyl-β-D-thiogalactoside 
JAK – janus-kinase 
kb – kilobase pairs 
kDa - kilodalton 
KS – Kaposi’s sarcoma 
KSHV - Kaposi’s sarcoma associated herpesvirus 
l - liter 
LIFR – leukemia inhibitory factor receptor 
MAPK - mitogen ativated protein kinase 
MCD - multicentric Castleman’s disease 
mg – milligram 
µg - microgramm 
min - minute 
MM – multiple myeloma 
ml - milliliter 
Mr – molecular weight 
ng - nanogarmm 
NF – nuclear factor 
NHS - N-hydroxysuccinimide 
OD – optic density 
o/n – over night 
ORF – open reading frame 
OSMR – oncostatin M receptor 
PCR – polymerase chain reaction 
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PEL - primary effusion lymphoma 
pNPP – 4-nitrophenyl phosphate 
POD - peroxidase 
P-STAT3 - phospho-STAT3 
RT – room temperatute 
scFv – single chain variable fragment 
SDS – sodium dodecyl sulfate 
SDS-PAGE - sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
sgp130 – soluble glycoprotein 130 
SHP-2 - Src homology 2 domain containing tyrosine phosphatase-2 
sIL-6R - soluble interleukin-6 receptor 
SOCS – suppressor of cytokine signaling 
SOE-PCR – splicing by overlap extension by PCR 
SOS - son of sevenless 
ssDNA – single stranded DNA  
STAT - signal transducer and activator of transcription 
TEMED – N,N,N’,N’-tetraethylenamine 
TNFα – tumor necrosis factor α 
TYK- tyrosine kinase 
VH – variable domain of heavy chain 
vIL-6 – viral interleukin-6 
VL - variable domain of light chain 
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8.2 Sequences 
 
A Nucleotide and amino acid sequence of vIL-6 (in p16b vector) 
      1 ggaattccatatgTTGCCGGACGCCCCCGAGTTTGAAAAGGATCTTCTCATTCAGAGACTCAATTGG ATG CTA TGG GTG ATC GAT GAA TGC  91     
      1                                                                     M   L   W   V   I   D   E   C    8       
 
     92 TTC CGC GAC CTC TGT TAC CGT ACC GGC ATC TGC AAG GGT ATT CTA GAG CCC GCT GCT ATT TTT CAT CTG AAA CTA  166    
      9 F   R   D   L   C   Y   R   T   G   I   C   K   G   I   L   E   P   A   A   I   F   H   L   K   L    33      
 
    167 CCA GCC ATC AAC GAT ACT GAT CAC TGC GGG TTA ATA GGA TTT AAT GAG ACT AGC TGC CTT AAA AAG CTC GCC GAT  241    
     34 P   A   I   N   D   T   D   H   C   G   L   I   G   F   N   E   T   S   C   L   K   K   L   A   D    58      
 
    242 GGC TTT TTC GAG TTC GAG GTG TTG TTT AAG TTT TTA ACG ACG GAG TTT GGA AAA TCA GTG ATA AAC GTG GAC GTC  316    
     59 G   F   F   E   F   E   V   L   F   K   F   L   T   T   E   F   G   K   S   V   I   N   V   D   V    83      
 
    317 ATG GAG CTT CTG ACG AAG ACC TTA GGA TGG GAC ATA CAG GAA GAG CTC AAT AAG CTG ACT AAG ACG CAC TAC AGT  391    
     84 M   E   L   L   T   K   T   L   G   W   D   I   Q   E   E   L   N   K   L   T   K   T   H   Y   S    108     
 
    392 CCA CCC AAA TTT GAC CGC GGT CTA TTA GGG AGG CTT CAG GGA CTT AAG TAT TGG GTG AGA CAC TTT GCT TCG TTT  466    
    109 P   P   K   F   D   R   G   L   L   G   R   L   Q   G   L   K   Y   W   V   R   H   F   A   S   F    133     
 
    467 TAT GTT CTG AGT GCA ATG GAA AAG TTT GCA GGT CAA GCG GTG CGT GTT TTG AAC TCT ATC CCA GAC GTG ACT CCT  541    
    134 Y   V   L   S   A   M   E   K   F   A   G   Q   A   V   R   V   L   N   S   I   P   D   V   T   P    158     
 
    542 GAC GTC CAC GAT AAG TGA ggatccgcg                                                                    568    
    159 D   V   H   D   K   *                                                                                164     
 
 
B Amino acid sequence of flag-vIL-6-his  
APLVDYKDDDDKALAKLPDAPEFEKDLLIQRLNWMLWVIDECFRDLCYTGICKGILEPA
AIFHLKLPAINDTDHCGLIGFNETSCLKKLADGFFEFEVLFKFLTTEFGKSVINVDVME
LLTKTLGWDIQEELNKLTKTHYSPPKFDRGLLGRLQGLKYWVRHFASFYVLSAMEKFAG
QAVRVLNSIPDVTPDVHDKGSHHHHHH* 
blue – flag-tag 
red – his-tag 
 
C Amino acid sequence of his-vIL-6 
APLVHHHHHHKLPDAPEFEKDLLIQRLNWMLWVIDECFRDLCYRTGICKGILEPAAIFH
LKLPAINDTDHCGLIGFNETSCLKKLADGFFEFEVLFKFLTTEFGKSVINVDVMELLTK
TLGWDIQEELNKLTKTHYSPPKFDRGLLGRLQGLKYWVRHFASFYVLSAMEKFAGQAVR
VLNSIPDVTPDVHDK* 
 red – his-tag 
 
D Nucleotide and amino acid sequence of vIL-6-GFP 
      1 CACTAGCTAGCGCCACC ATG TGC TGG TTC AAG TTG TGG TCT ATC TTG CTG GTA GGT TCA CTG CTG GTA TCT GGA ACG    77     
      1                   M   C   W   F   K   L   W   S   I   L   L   V   G   S   L   L   V   S   G   T      20      
 
     78 CGG GGC AAG TTG CCG GAC GCC CCC GAG TTT GAA AAG GAT CTT CTC ATT CAG AGA CTC AAT TGG ATG CTA TGG GTG  152    
     21 R   G   K   L   P   D   A   P   E   F   E   K   D   L   L   I   Q   R   L   N   W   M   L   W   V    45      
 
    153 ATC GAT GAA TGC TTC CGC GAC CTC TGT TAC CGT ACC GGC ATC TGC AAG GGT ATT CTA GAG CCC GCT GCT ATT TTT  227    
     46 I   D   E   C   F   R   D   L   C   Y   R   T   G   I   C   K   G   I   L   E   P   A   A   I   F    70      
 
    228 CAT CTG AAA CTA CCA GCC ATC AAC GAT ACT GAT CAC TGC GGG TTA ATA GGA TTT AAT GAG ACT AGC TGC CTT AAA  302    
     71 H   L   K   L   P   A   I   N   D   T   D   H   C   G   L   I   G   F   N   E   T   S   C   L   K    95      
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    303 AAG CTC GCC GAT GGC TTT TTC GAA TTC GAG GTG TTG TTT AAG TTT TTA ACG ACG GAG TTT GGA AAA TCA GTG ATA  377    
     96 K   L   A   D   G   F   F   E   F   E   V   L   F   K   F   L   T   T   E   F   G   K   S   V   I    120     
 
    378 AAC GTG GAC GTC ATG GAG CTT CTG ACG AAG ACC TTA GGA TGG GAC ATA CAG GAA GAG CTC AAT AAG CTG ACT AAG  452    
    121 N   V   D   V   M   E   L   L   T   K   T   L   G   W   D   I   Q   E   E   L   N   K   L   T   K    145     
 
    453 ACG CAC TAC AGT CCA CCC AAA TTT GAC CGC GGT CTA TTA GGG AGG CTT CAG GGA CTT AAG TAT TGG GTG AGA CAC  527    
    146 T   H   Y   S   P   P   K   F   D   R   G   L   L   G   R   L   Q   G   L   K   Y   W   V   R   H    170     
 
    528 TTT GCT TCG TTT TAT GTT CTG AGT GCA ATG GAA AAG TTT GCA GGT CAA GCG GTG CGT GTT TTG AAC TCT ATC CCA  602    
    171 F   A   S   F   Y   V   L   S   A   M   E   K   F   A   G   Q   A   V   R   V   L   N   S   I   P    195     
 
    603 GAC GTG ACT CCT GAC GTC CAC GAT AAG TCT CGA GCG GCC GCC GCC ACC ATG AGC AAG GGC GAG GAA CTG TTC ACT  677    
    196 D   V   T   P   D   V   H   D   K   S   R   A   A   A   A   T   M   S   K   G   E   E   L   F   T    220     
 
    678 GGC GTG GTC CCA ATT CTC GTG GAA CTG GAT GGC GAT GTG AAT GGG CAC AAA TTT TCT GTC AGC GGA GAG GGT GAA  752    
    221 G   V   V   P   I   L   V   E   L   D   G   D   V   N   G   H   K   F   S   V   S   G   E   G   E    245     
 
    753 GGT GAT GCC ACA TAC GGA AAG CTC ACC CTG AAA TTC ATC TGC ACC ACT GGA AAG CTC CCT GTG CCA TGG CCA ACA  827    
    246 G   D   A   T   Y   G   K   L   T   L   K   F   I   C   T   T   G   K   L   P   V   P   W   P   T    270     
 
    828 CTG GTC ACT ACC TTC ACC TAT GGC GTG CAG TGC TTT TCC AGA TAC CCA GAC CAT ATG AAG CAG CAT GAC TTT TTC  902    
    271 L   V   T   T   F   T   Y   G   V   Q   C   F   S   R   Y   P   D   H   M   K   Q   H   D   F   F    295     
 
    903 AAG AGC GCC ATG CCC GAG GGC TAT GTG CAG GAG AGA ACC ATC TTT TTC AAA GAT GAC GGG AAC TAC AAG ACC CGC  977    
    296 K   S   A   M   P   E   G   Y   V   Q   E   R   T   I   F   F   K   D   D   G   N   Y   K   T   R    320     
 
    978 GCT GAA GTC AAG TTC GAA GGT GAC ACC CTG GTG AAT AGA ATC GAG CTG AAG GGC ATT GAC TTT AAG GAG GAT GGA  1052   
    321 A   E   V   K   F   E   G   D   T   L   V   N   R   I   E   L   K   G   I   D   F   K   E   D   G    345     
 
   1053 AAC ATT CTC GGC CAC AAG CTG GAA TAC AAC TAT AAC TCC CAC AAT GTG TAC ATC ATG GCC GAC AAG CAA AAG AAT  1127   
    346 N   I   L   G   H   K   L   E   Y   N   Y   N   S   H   N   V   Y   I   M   A   D   K   Q   K   N    370     
 
   1128 GGC ATC AAG GTC AAC TTC AAG ATC AGA CAC AAC ATT GAG GAT GGA TCC GTG CAG CTG GCC GAC CAT TAT CAA CAG  1202   
    371 G   I   K   V   N   F   K   I   R   H   N   I   E   D   G   S   V   Q   L   A   D   H   Y   Q   Q    395     
 
   1203 AAC ACT CCA ATC GGC GAC GGC CCT GTG CTC CTC CCA GAC AAC CAT TAC CTG TCC ACC CAG TCT GCC CTG TCT AAA  1277   
    396 N   T   P   I   G   D   G   P   V   L   L   P   D   N   H   Y   L   S   T   Q   S   A   L   S   K    420     
 
   1278 GAT CCC AAC GAA AAG AGA GAC CAC ATG GTC CTG CTG GAG TTT GTG ACC GCT GCT GGG ATC ACA CAT GGC ATG GAC  1352   
    421 D   P   N   E   K   R   D   H   M   V   L   L   E   F   V   T   A   A   G   I   T   H   G   M   D    445     
 
   1353 GAG CTG TAC AAG TGA GC                                                                               1369   
    446 E   L   Y   K   *                                                                                    450     
 
 
green – GFP 
 
E Nucleotide and amino acid sequence of MAV (in pIT1 vector) 
      1 ATG GCC GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA CAG CCT GGG GGG TCC CTG AGA CTC TCC TGT GCA  75     
      1 M   A   E   V   Q   L   L   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A    25      
 
     76 GCC TCT GGA TTC ACC TTT AGC AGC TAT GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC  150    
     26 A   S   G   F   T   F   S   S   Y   A   M   S   W   V   R   Q   A   P   G   K   G   L   E   W   V    50      
 
    151 TCA GAT ATT CGG GGG CGG GGT CCT CCG ACA GGT TAC GCA GAC TCC GTG AAG GGC CGG TTC ACC ATC TCC AGA GAC  225    
     51 S   D   I   R   G   R   G   P   P   T   G   Y   A   D   S   V   K   G   R   F   T   I   S   R   D    75      
 
    226 AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG A*A GCC *AG GAC ACG GCC GTA TAT TAC TGT GCG AAA  300    
     76 N   S   K   N   T   L   Y   L   Q   M   N   S   L   X   A   X   D   T   A   V   Y   Y   C   A   K    100     
 
    301 AGG ATG TGG GGT TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA  375    
    101 R   M   W   G   F   D   Y   W   G   Q   G   T   L   V   T   V   S   S   G   G   G   G   S   G   G    125     
 
    376 GGT GGC AGC GGC GGT GGC GGG TCG ACG GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA  450    
    126 G   G   S   G   G   G   G   S   T   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S   V   G    150     
 
    451 GAC AGA GTC ACC ATC ACT TGC CGG GCA AGT CAG AGC ATT AGC AGC TAT TTA AAT TGG TAT CAG CAG AAA CCA GGG  525    
    151 D   R   V   T   I   T   C   R   A   S   Q   S   I   S   S   Y   L   N   W   Y   Q   Q   K   P   G    175     
 
    526 AAA GCC CCT AAG CTC CTG ATC TAT GGG GCA TCC CGC TTG CAA AGT GGG GTC CCA TCA AGG TTC AGT GGC AGT GGA  600    
    176 K   A   P   K   L   L   I   Y   G   A   S   R   L   Q   S   G   V   P   S   R   F   S   G   S   G    200     
 
    601 TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT GCA ACT TAC TAC TGT CAA CAG GCT  675    
    201 S   G   T   D   F   T   L   T   I   S   S   L   Q   P   E   D   F   A   T   Y   Y   C   Q   Q   A    225     
 
    676 TGG CAT CTT CCT TTG ACG TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA CGG GCG GCC GCA GAA CAA AAA CTC ATC  750    
    226 W   H   L   P   L   T   F   G   Q   G   T   K   V   E   I   K   R   A   A   A   E   Q   K   L   I    250     
 
    751 TCA GAA GAG GAT CTG AAT GGG GCC GCA TAG                                                              780    
    251 S   E   E   D   L   N   G   A   A   *                                                                260     
 
  blue – myc-tag 
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F Nucleotide and amino acid sequence of MAV-KDEL 
      1 CACGTTTAAACGCCACC ATG AAC TCC TTC TCC ACA AGC GCC TTC GGT CCA GTT GCC TTC TCC CTG GGG CTG CTC CTG    77     
      1                   M   N   S   F   S   T   S   A   F   G   P   V   A   F   S   L   G   L   L   L      20      
  
     78 GTG TTG CCT GCT GCC TTC CCT GCC CCA GTA CAC GTG ATG GCC GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG  152    
     21 V   L   P   A   A   F   P   A   P   V   H   V   M   A   E   V   Q   L   L   E   S   G   G   G   L    45      
 
    153 GTA CAG CCT GGG GGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTT AGC AGC TAT GCC ATG AGC TGG  227    
     46 V   Q   P   G   G   S   L   R   L   S   C   A   A   S   G   F   T   F   S   S   Y   A   M   S   W    70      
 
    228 GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA GAT ATT CGG GGG CGG GGT CCT CCG ACA GGT TAC GCA  302    
     71 V   R   Q   A   P   G   K   G   L   E   W   V   S   D   I   R   G   R   G   P   P   T   G   Y   A    95      
 
    303 GAC TCC GTG AAG GGC CGG TTC ACC ATC TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG  377    
     96 D   S   V   K   G   R   F   T   I   S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L    120     
 
    378 A*A GCC *AG GAC ACG GCC GTA TAT TAC TGT GCG AAA AGG ATG TGG GGT TTT GAC TAC TGG GGC CAG GGA ACC CTG  452    
    121 X   A   X   D   T   A   V   Y   Y   C   A   K   R   M   W   G   F   D   Y   W   G   Q   G   T   L    145     
 
    453 GTC ACC GTC TCG AGC GGT GGA GGC GGT TCA GGC GGA GGT GGC AGC GGC GGT GGC GGG TCG ACG GAC ATC CAG ATG  527    
    146 V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   T   D   I   Q   M    170     
 
    528 ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA GGA GAC AGA GTC ACC ATC ACT TGC CGG GCA AGT CAG AGC ATT  602    
    171 T   Q   S   P   S   S   L   S   A   S   V   G   D   R   V   T   I   T   C   R   A   S   Q   S   I    195     
 
    603 AGC AGC TAT TTA AAT TGG TAT CAG CAG AAA CCA GGG AAA GCC CCT AAG CTC CTG ATC TAT GGG GCA TCC CGC TTG  677    
    196 S   S   Y   L   N   W   Y   Q   Q   K   P   G   K   A   P   K   L   L   I   Y   G   A   S   R   L    220     
 
    678 CAA AGT GGG GTC CCA TCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC ACT CTC ACC ATC AGC AGT CTG CAA  752    
    221 Q   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D   F   T   L   T   I   S   S   L   Q    245     
 
    753 CCT GAA GAT TTT GCA ACT TAC TAC TGT CAA CAG GCT TGG CAT CTT CCT TTG ACG TTC GGC CAA GGG ACC AAG GTG  827    
    246 P   E   D   F   A   T   Y   Y   C   Q   Q   A   W   H   L   P   L   T   F   G   Q   G   T   K   V    270     
 
    828 GAA ATC AAA CGG GCG GCC GCA GAA CAA AAA CTC ATC TCA GAA GAG GAT CTG AAT CCG CGG AAA GAC GAA CTC TAG  902    
    271 E   I   K   R   A   A   A   E   Q   K   L   I   S   E   E   D   L   N   P   R   K   D   E   L   *    295     
 
    903 GTTTAAACCAC                                                                                          913    
blue – myc-tag 
red – retention sequence 
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